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Human papilloma virus (HPV) infection is the most common etiological agent of cervical cancer, the 
most common cancer in women in Africa. The lifecycle of HPV has historically made the virus difficult 
to culture in vitro, and this has hindered the study of the virus, as well as development of vaccines. 
The development of synthetic HPV particles, such as virus-like particles (VLPs) and more recently 
pseudovirions (PsVs), has allowed for unprecedented insights into the lifecycle and immunology of 
this virus. This has led to the development of two currently available vaccines, namely Cervarix™ and 
Gardasil®. Cervarix offers protection against high-risk HPV types 16 and 18, while Gardasil offers 
further protection against types 6 and 11. Both of these vaccines are based on major capsid protein 
L1 Virus-like particles (VLPs). While these vaccines show no loss of efficacy, further work is underway 
to develop a second generation HPV vaccine that is cheap, stable and displays cross-neutralising 
activity across a broader range of HPV types.  
 
The recent efficient methods for intracellular production of HPV PsVs encapsidating non-
papillomaviral DNA (pseudogenomes) has allowed for development of a robust and sensitive 
pseudovirion-based neutralisation assay (PBNA), which has become the gold standard neutralisation 
assay for the testing of candidate HPV vaccines. The currently accepted PsV production method 
utilises mammalian cell culture to produce HPV PsVs, encapsidating a SEAP reporter plasmid, at high 
titres. While this is an effective method of PsV production, mammalian cell culture is expensive and 
time-consuming.  
 
Transient recombinant protein expression in plants offers a rapid and cost-effective alternative to 
mammalian cell culture. Here, we developed a method of high-titre HPV PsV production in plants. 
The autonomously replicating plant vector, pRIC3, was modified to include mammalian reporter 
cassettes encoding luc or SEAP, for the production of reporter pseudogenomes DNA in plants by 
Agrobacterium-mediated transient expression. The SEAP and luc cassettes were introduced into 
pRIC3 upstream of the plant cassette, which was included only to increase the final pseudogenome 
size for efficient packaging into PsVs. The SEAP cassette was also introduced into pRIC3 in place of 
the plant cassette, to form a smaller pseudogenome. Thus three vectors were created, namely 
pRIC3-mSEAP+ (6.4Kbp pseudogenome), pRIC3-mluc+ (7.4Kbp pseudogenome), and pRIC3-mSEAP 
(4.8Kbp pseudogenome), which would produce pseudogenomes that covered the full range of 
plasmid sizes incorporated by assembling HPV capsid proteins in vivo. All three replicating vectors 
demonstrated the formation of a replicon, and autonomous replication, in Nicotiana benthamiana 















constructs pTRAc-hL1 and pTRAc-hL2, which encode human-codon optimised forms of HPV-16 major 
and minor capsid proteins, respectively. It was expected that encapsidation of replicon DNA as a 
pseudogenome into assembling HPV particles would result in the production of HPV PsVs in planta. 
In addition, L1 and L2 were expressed in the absence of replicon DNA to form L1/L2 VLPs. Particles 
were extracted from plant material at four days post-infiltration, using a modified VLP extraction 
protocol. HPV particles were separated on the basis of isopycnic caesium chloride density gradient 
ultracentrifugation, dialysed against high-salt PBS and identified by fractionation and probing with 
an anti-L1 antibody. Particles corresponding to the buoyant density of pseudovirions were seen in 
samples with or without replicon DNA. Western blotting showed that all particles had incorporated 
both L1 and L2 proteins. Particles were digested with proteinase K to release encapsidated 
pseudogenome DNA and PCR confirmed the presence of replicon-specific DNA in each PsV. Electron 
microscopy confirmed the presence of HPV-16 PsVs in all samples.  
 
To test whether plant-produced HPV-16 PsVs could be used in pseudovirion-based neutralisation 
assays, mammalian cells were pseudoinfected with purified mSEAP, mSEAP+ or mluc+ PsVs. mSEAP 
and mluc+ PsVs elicited a reporter gene response in mammalian cells 72 hours post-infection using 
SEAP and luciferase assays, respectively, while mSEAP+ PsVs showed no reporter gene expression in 
mammalian cells. PsVs incubated with a known HPV-16 neutralising antibody showed partial 
neutralisation of mSEAP PsVs and complete neutralisation of mluc+ PsVs 
 
To our knowledge, this is the first demonstration of production of HPV PsVs in plants, and their use 
in a PBNA. Further, it is the first demonstration of production of HPV L1/L2 VLPs in plants. While 
much work remains to improve plant production and purification methods of PsVs, as well as 
mammalian expression following PsV pseudoinfection, this is an important step towards a new 
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Chapter 1: Literature Review 
1.1. Introduction 
 
Human Papillomaviruses (HPV) are a group of viruses in the family Papillomaviridae. They are non-
enveloped, double-stranded DNA viruses, with a genome of approximately 8Kb (de Villiers et al., 
2004). The genome contains 8 open reading frames (ORFs) encoding six early genes E1, E2, E4, E5, 
E6, and E7, and two late genes L1 and L2 (Figure 1.1).  L1 and L2 are the major and minor capsid 
proteins, respectively. L1 forms pentamers, or capsomeres, that assemble along with minor capsid 
protein L2 to form a T=7 icosahedral lattice (See Fig. 1.1B) (Conway and Meyers, 2009). 
 
There are 16 genera in the family Papillomaviridae; viruses in five of these genera – Alpha, Beta, 
Gamma, Mu and Nu – infect the squamous and cutaneous epithelia of humans and are referred to 
as HPVs (de Villiers et al., 2004; zur Hausen, 2000). Within these genera there are over 200 types 
identified to date, which are classified based on L1 major capsid protein sequence homology 
(Conway and Meyers, 2009; de Villiers et al., 2004).  These can be divided into those that cause 
benign lesions, known as “low-risk” types, and those that cause malignant lesions, known as “high-
risk” types. HPV-16 and HPV-18 are two high-risk types responsible for the vast majority of cervical 
cancers (Bosch et al., 2008). Infection with a high-risk HPV type is now considered to play a causative 
role in the progression to cervical neoplasia (Walboomers et al., 1999). Cervical cancer is the second 
most common cancer in women worldwide; it is of particular concern in developing countries, where 
A B 
Figure 1.1| HPV structure and genome organisation (A) genome map of HPV-16. E1, E2, E4 E5 E6 and E7 
are early genes, L1, the major capsid protein, and L2, the minor capsid protein, are late genes. LRR, long 
regulatory region (Reproduced from Gerard, 2006). (B) Model of outer surface structure of HPV-16 (L1 in 















the lack of regular cervical screening results in a far higher burden of disease and mortality than in 
developed countries (Ngoma, 2006). 
 
The prevalence and persistence of HPV, as well as cervical cancer, worldwide, has been widely 
documented (Burchell et al., 2006; Crow, 2012; Kawana et al., 2009; Walboomers et al., 1999). 
Recent estimates suggest that approximately 10.4% of women with normal cervical cytology harbour 
an HPV infection, while the overall estimate of infected males stands at approximately 7.9% 
(Burchell et al., 2006; Partridge and Koutsky, 2006). The majority of cervical HPV infections that 
reach the stage of low-grade lesions, or Cervical Intraepithelial Neoplasia (CIN) 1, are cleared by the 
body within 1-2 years of infection (Crow, 2012; Hopfl et al., 2000; Jenson et al., 1991). However,  
persistent infection causes spontaneous progression to neoplasia in 1 in 200-300 women if left 
untreated (Kawana et al., 2009). 
 
Several key challenges to the efficient prevention of HPV transmission and treatment of infections 
have been identified, which if solved, would pave the way to a significant reduction of HPV- induced 
cervical carcinomas. These include, but are not limited to:  
a) the development of a cheap and effective method to produce biologically sound and 
infectious HPV virions for testing and development of vaccines 
b) identification of a reliable immune correlate of protection 
c) identification of broadly cross-neutralising epitopes for vaccination against multiple HPV 
types 
d) an overall decrease in cost of testing and vaccine production, to better confront the burden 
of cervical cancer in developing countries. 
 
While several of these challenges have been solved, at least in part, much remains to be done to 
decrease the occurrence of HPV-induced cervical cancer, as well as other HPV-related diseases. This 
review will examine the current state of progress in addressing these challenges, with a particular 
focus on the production of synthetic virions for testing and development, and a reduction in overall 
















1.2. HPV replication and assembly 
1.2.1. HPV infection  
 
HPVs are extremely effective infectious agents, in that they induce only chronic infections, and rely 
almost wholly on host cell replication and differentiation to spread (Stanley, 2008). Invasive HPV 
enters the human body through microwounds in the epithelia, which expose the basal epithelium to 
invasion (see Figure 1.2A) (Longworth and Laimins, 2004). The exact mode of cell entry is unknown, 
although it is known that cell surface heparan sulphate is required (Giroglou et al., 2001; Joyce et al., 
1999). It is has been shown that both the C- and N-terminus of the L2 minor capsid protein possess a 
nuclear localisation signal (NLS); further evidence shows that L2 is implicated in nuclear localisation 
of the virus once inside the cell (Fay et al., 2004; Holmgren et al., 2005; Pereira et al., 2009). Once 
inside the nuclei of the basal epithelia, the viral early ORFs (which encode proteins E1, E2, E4, E5, E6 
and E7) are transcribed in a viral gene expression cascade(Fig. 1.2 B)(Conway and Meyers, 2009). E1 
and E2 are the first proteins transcribed, and are responsible for the recruitment of cellular 
replicative machinery (Conger et al., 1999; Mohr et al., 1990). These early events result in between 
20 and 100 episomal copies of the HPV minichromosome per cell (Stanley, 2008). Following this 
step, infected keratinocyte stem cells follow their normal lifecycle. Cells  migrate through the 
epithelial strata while undergoing a process of terminal differentiation (Pang et al., 1993). In contrast 
with non-infected keratinocytes, HPV-infected keratinocytes remain mitotically active after 
Figure 1.2 | Life cycle of HPV infection (A) HPV entry into the basal stem cells. (B) Episomal replication via 
early gene expression. (C) Viral genome amplification and late gene expression. (D) Virion assembly and 



















detachment from the basal layer, due to the activity of the E7 oncoprotein (Morris et al., 1993). 
Once the cells are terminally differentiated, this signals the transcription of the L1 and L2 ORFs under 
control of the late viral promoter (Fig. 1.2C) (Barksdale and Baker, 1993). L1 and L2 proteins then 
assemble and encapsidate the HPV genome to form infectious virions (Fig. 1.2D).  
 1.2.2. Virion structure 
 
Fully assembled HPV virions are composed of 360 L1 molecules, and a less clear number of L2 
molecules. Current best estimates are that the ratio of L1 to L2 is 30:1, although a estimates of as 
much as 5:1 have been suggested, based on stochiometric analysis and in vitro production methods 
(Conway and Meyers, 2009; Finnen et al., 2003; Pereira et al., 2009). The L1 protein forms 
capsomeres – radially symmetric pentamers of the major capsid protein with a central “hole” or 
indentation (see Fig 1.1B). There are 72 capsomeres in a mature capsid, with a T=7 icosahedral 
symmetry (Doorbar, 2005). Cryoelectron microscopy analysis of HPV-16 pseudovirions by Buck et al. 
(2008) and Trus et al. (1997) has shown individual L2 molecules to be associated with the “holes” in 
the assembled capsomeres, and that the L1:L2 ratio varies based on concentration of L2 when 
produced in vitro. Their data suggests that an L2 molecule may associate with every capsomere in 
the virion, resulting in a ratio of 5:1, although evidence from in vivo assembly studies suggests that 
this is unlikely to be the case in natural virion assembly (Pereira et al., 2009). Virions are formed via 
intercapsomeric hydrophobic interactions of helices 2, 3 and 4 of the C-terminal region of L1 (Modis 
et al., 2002). This binding is stabilised by several disulphide bonds, both intra- and intercapsomeric 
(Buck et al., 2005b; Fligge et al., 2001; Sapp et al., 1998). 
1.2.3. Virion assembly 
 
Capsid assembly of HPV virions in vivo has not been fully elucidated, in part due to the difficulty of 
culturing these viruses. However, recent developments in in vitro production methods, examined in 
more depth in Section 1.3., have allowed a new level of understanding of the assembly process and 
the requirements for production of infectious virions.  
 
The exact molecular interactions required for virion assembly remain unclear (Conway and Meyers, 
2009). Replication of the HPV genome has been shown to occur in the vicinity of the nuclear domain 
ND10 (Swindle et al., 1999). ND10 has been shown to be the localisation site for expressed L2 in 
natural infections, and it has recently become clear that this localisation event is required for capsid 
assembly (Day et al., 1998; Florin et al., 2002). Further, Florin et al. (2002) showed that the presence 















(1993a) that L1 co-localises to L2 in vitro, and Becker et al. (2004), who showed that nuclear 
localisation of L1 was  required for L2 incorporation into the capsid. Subsequent to expression of L2, 
L1 is expressed in the cytoplasm, where it pentamerises to form capsomeres through disulphide 
bonding (Bird et al., 2008; McCarthy et al., 1998). Capsomeres bind to several karyopherin nuclear 
transport proteins, via an NLS found in the C-terminal DNA-binding domain of L1, and are 
transported to the nucleus (Bird et al., 2008; Li et al., 1997). Further, it has been suggested that 
binding of karyopherins prevents capsid assembly in the cytoplasm (Bird et al., 2008). 
 
The first step in viral capsid assembly is the establishment of a nucleation point, usually a dimer 
around which the capsid can assemble (Zandi et al., 2006). Several models of nucleation have been 
suggested for HPV. Early models were based on the closely related polyomaviruses – assembly of 
these viruses starts as five pentamers of the major capsid protein VP1 around one pentamer (Casini 
et al., 2004; Stehle et al., 1994). The work of Casini et al.(2004), wherein the assembly kinetics of L1 
were investigated using light scattering, suggested an alternative model for in vitro capsid formation 
– that of nucleation around dimerised capsomeres. However, this analysis was performed in the 
absence of L2, and it is likely that in natural infections, capsid assembly is a far more complex 
phenomenon. There are several lines of evidence for a role for L2 in nucleation, capsid assembly and 
encapsidation of DNA, although there is little agreement on the exact role played by L2 in these 
processes.   
 
L2 possesses a strongly hydrophobic C-terminal domain which has been shown to bind L1. There is 
evidence that in bovine papillomavirus, L2 binds L1 prior to assembly of the capsid, and it has been 
suggested that this binding triggers the assembly process (Finnen et al., 2003; Okun et al., 2001). In 
contrast to this, it has been shown that L2 is involved in intercapsomeric interactions with other L2 
molecules via its N- and C-terminals, and these interactions may be responsible for initial capsid 
formation (Buck et al., 2008; Ishii et al., 2005).  
 
Most studies of the association of DNA with the HPV capsid proteins have utilised synthetic virions 
such as virus-like particles (VLPs) and pseudovirions (PsVs) in vitro. There is some disagreement over 
the exact requirements for, and respective roles of L1 and L2 in DNA binding. Several investigators 
have shown that both L1 and L2 are required to package DNA effectively (Ma et al., 2011; Okun et 
al., 2001; Stauffer et al., 1998), while others have suggested that L2 is not required at all (Touze and 
Coursaget, 1998; Unckell et al., 1997), and still others that L1 is not required (Zhou et al., 1993a). 















encapsidation of DNA 10-fold. There is no clear evidence for L1 or L2 binding to specific sequences of 
DNA. Rather, evidence points to non-specific associations of certain protein domains with DNA 
based on basic interior domains and overall charge – a C-terminal region of L1, and highly charged 
regions in both the C- and N-terminus of L2 (Fay et al., 2004; Garcea and Gissmann, 2004; Li et al., 
1997; Pereira et al., 2009). Notably, incorporation of a putative L1 DNA binding region into an 
unrelated viral capsid protein conferred the ability to encapsidate DNA (El Mehdaoui et al., 2000). 
 
Interestingly, the L1 NLS overlaps with the C-terminal DNA binding region, and it has been suggested 
that the karyopherins which bind L1 for nuclear transport play a role as chaperones for virion 
assembly. This is supported by evidence that L1 binds karyopherin α2 and DNA simultaneously (Bird 
et al., 2008). The karyopherin α2β1 complex has been shown to facilitate nuclear transport of both 
L1 and L2, and karyopherin α2 binds L2 in a similar fashion to L1 – via an NLS in the C-terminal DNA 
binding domain (Bird et al., 2008; Fay et al., 2004). Previous studies have suggested a role for 
chaperone hsp70 in mediating both assembly and disassembly of papilloma- and polyomavirus 
capsids (Chromy et al., 2006; Chromy et al., 2003).  
 
DNA incorporated into HPV virions has been shown to ffect the structure of the mature virion. 
Fligge et al. (2001) showed that incorporation of DNA increased disulphide crosslinking between L1 
in the assembled capsid, and provided partial protection against trypsin cleavage. DNA in HPV virions 
is associated with cellular histones in chromatin-like structures (Conway and Meyers, 2009). The 
presence of histones in mature virions has been shown to increase infectivity 4-5 fold when 
compared  to encapsidated naked plasmid DNA (Fligge et al., 2001).  
 
In summary, HPV virion assembly occurs in several distinct steps. It is initiated by the late viral 
promoter, and starts with localisation of L2 protein, and the HPV genome, to ND10 sites in the 
nucleus. L1 expression follows soon after; the protein forms capsomeres in the cytoplasm before 
being transported to the nucleus by karyopherins. It is likely that L2 binding of capsomeres provides 
the nucleation point for capsid assembly, and that assembly is mediated by inter-L2 bonds. 
Encapsidation of HPV DNA occurs through DNA-protein interactions at non-specific DNA binding 
domains on the interior surfaces of both L1 and L2, and this encapsidation of DNA plays a role in 
stabilising the assembled virion.  
 
While our current understanding of HPV assembly and DNA encapsidation is not complete, 















virus in recent years. This is due in no small part to the development of recombinant capsid 
production capabilities, which have allowed a level of study not previously achievable. 
1.3. Synthetic HPV particles 
 
Until recently, an inability to produce papillomavirus virions in vitro was a major stumbling block to 
the study of this virus. Two methods have recently been described, namely xenografting and 
organotypic raft culture, for the production of infectious virus. The xenograft model uses HPV-
infected human epithelial tissue, implanted in athymic mice, to produce cysts in which HPV virions 
are produced. These cysts can be harvested, and purified for HPV virions (Kreider et al., 1987). 
Organotypic raft culture utilises 3T3 fibroblasts and human epidermal cells to establish stable 
organotypic ‘rafts’ in vitro (Rheinwald and Green, 1975). This system provides differentiating 
keratinocytes, in which papillomaviral DNA has been demonstrated to replicate and produce virions 
(Meyers et al., 1992; Meyers et al., 1997). While these models are important for the study of 
infectious papillomavirus, they remain expensive, time-consuming, and not particularly efficient 
(Conway and Meyers, 2009). Synthetic HPV particles (i.e. those particles produced by transfection of 
papillomaviral DNA into an expression system; namely VLPs, QVs and PsVs) provide a cheaper and 
easier production approach for the study of papillomavirus structure and infectious behaviour. 
1.3.1 Virus-like particles (VLPs) 
 
In vivo, HPV capsids are produced only in terminally differentiated keratinocytes (Barksdale and 
Baker, 1993), a strategy which allows the virus to avoid the host inflammatory response (Stanley, 
2008). For many years, this feature of HPV made it particularly difficult to study the immunogenic 
and structural features of the mature HPV capsid, and in particular inhibited development of an 
effective vaccine (Hagensee et al., 1993; Kirnbauer et al., 1992). The last 20 years, however, has seen 
the development of several methods and systems for the production of HPV VLPs. Early efforts 
utilised mammalian epithelial cells in culture, transfected with vaccinia viral vectors, to produce VLPs 
(Hagensee et al., 1993; Kirnbauer et al., 1992). These were quickly followed by production of VLPs of 
various HPV types in insect cells (Christensen et al., 1994; Roden et al., 1996; Senger et al., 2009; 
Volpers et al., 1994), bacteria (Nardelli-Haefliger et al., 1997), yeast (Cook et al., 1999; Hofmann et 
al., 1995; Mach et al., 2006), and more recently in plants (Biemelt et al., 2003; Maclean et al., 2007; 
Patel et al., 2009). It has been shown that L1 alone can assemble to form stable, uniform VLPs in all 
of these systems, while L1 and L2 have been produced in most (with the exception of plants). 















resemble the native papillomavirus virions, and are highly immunogenic (Hagensee et al., 1993; 
Kirnbauer et al., 1992; Rose et al., 1993). 
1.3.2. Quasivirions (QVs) and pseudovirions (PsVs) 
 
Production of recombinant HPV VLPs was an important step forward, in that it allowed researchers 
to analyse and describe the virus structure and activity in ways not previously possible, and allowed 
for the development of two highly successful vaccines (Stanley, 2008). Soon after, several 
researchers showed that these VLPs packaged papillomavirus DNA in vitro. Zhou et al. (1993a) 
showed that recombinant Bovine Papillomavirus (BPV-1) L1 and L2 packaged the BPV-1 genome in 
B2 cells to produce infectious particles, and Roden et al. (1996) demonstrated that when cells 
containing an autonomously replicating bovine papillomavirus genome were transfected with HPV-
16 L1 and L2, the genomes were packaged efficiently to produce quasivirions (QVs). 
 
HPV QVs are now produced almost exclusively in HEK293T or HEK293TT cells, via a method 
established by Pyeon et al. (Pyeon et al., 2005; Smith et al., 2007). They have been shown to be 
similar in infectious titer and neutralisation characteristics to native virions, and can produce 
papillomas (Conway and Meyers, 2009; Pyeon et al., 2005). While the behaviour and structure of 
QVs seems to be very similar to native virions, they have not yet been conclusively shown to be 
indistinguishable, and some work remains before these can be considered as replacements for 
native virions in experimental procedures.  
 
 Soon after the production of th  first VLPs and QVs,  Unckell et al. (1997), Touze and Coursaget 
(1998), and Stauffer et al. (1998) demonstrated that the L1 and L2 capsid proteins packaged non-
papillomaviral plasmid DNA with similar efficiency. These particles, called pseudovirions (PsVs), were 
shown to transfer plasmid DNA into epithelial cells in a manner indistinguishable to that of infectious 
HPV virions. All three groups used a reporter plasmid encoding the lacZ gene, while Touze and 
Coursaget also tested a GFP reporter gene, and Stauffer et al. showed that a puromycin resistance 
gene could confer antibiotic resistance to pseudovirion-infected cells. Touze and Coursaget further 
demonstrated that HPV VLPs preferentially packaged plasmid DNA of 5-8kbp, and established that 
packaging efficiency was proportional to plasmid size (Buck et al., 2004; Touze and Coursaget, 1998) 
 
Since that time, several other groups have achieved PsV synthesis through a variety of methods. 
These can be roughly sorted into two major groups in terms of approach to production. The first, as 















signals of L1 and L2 proteins. Broadly speaking, this approach utilises traditional methods of VLP 
production as described in Section 1.3.1. These VLPs are then disassembled in vitro by chemical 
means, incubated with the plasmid DNA to be encapsidated, and reassembled through incremental 
increases in CaCl2 concentration. Several groups have successfully utilised this approach for the 
production of infectious PsVs, using VLPs produced in insect or mammalian cells (Kawana et al., 
1998; Oh et al., 2004; Shi et al., 2001; Touze and Coursaget, 1998; Zhang et al., 2004). A variation of 
this approach is demonstrated by  Yeager et al. (2000), who chemically coupled a reporter plasmid 
to yeast-produced VLPs.  
 
While the disassembly-reassembly method is nominally successful in producing PsVs, and continues 
to be used for studies utilising HPV PsVs, a second, more effective method has been developed. This 
method, best demonstrated by the Schiller group, exploits the intracellular virion assembly 
mechanisms used by the virus in natural infections to assemble PsVs in mammalian (Liu et al., 2001; 
Stauffer et al., 1998; Unckell et al., 1997), insect (Zhao et al., 1998), or yeast (Rossi et al., 2000) cells. 
In mammalian and insect cell systems, this is achieved through transient expression by L1 and L2 
expression plasmids, as well as a reporter plasmid for encapsidation (Buck et al., 2004). In yeast, this 
was achieved through two-step stable transformation of Saccharomyces cerivisiae, first for the 
production of HPV VLPs, and second with the reporter  plasmid to be encapsidated (Rossi et al., 
2000). Using a specially developed cell line – HEK293TT, encoding two copies of the SV40 T-antigen 
for improved viral replication – Buck et al. (2004) demonstrated a 10-million fold improvement in 
efficiency on earlier PsV production methods. This clear evidence for the success of intracellular 
assembly of PsVs is supported by experimental evidence that despite a significantly higher level of L1 
being present in the in vitro system, PsVs produced by this intracellular method had higher gene 
transfer efficiency into infected cells than PsVs produced by reassembly methods (Fleury et al., 
2008b; Peng et al., 2011). It is likely that this improved assembly and infectivity is due to not yet fully 
defined mechanisms of virion assembly present in the nucleus of cell systems utilised for PsV 
production, which are not present in the chemical milieu found in disassembly-reassembly systems. 
1.3.3. Infectivity and immunogenicity of synthetic HPV particles 
 
While advances in synthetic HPV particle technology have allowed giant leaps forward in the study 
and treatment of the virus and concomitant disease, this progress has rightly been tempered with 
caution: an important aspect in the production of synthetic HPV virions is whether their 
morphological, infective and behavioural characteristics accurately match those of the natural virion 















and testing of potential HPV vaccines. Accordingly, there has been some investigation into the 
comparative morphology, infectivity and immunogenicity of HPV VLPs and PsVs.  
 
While the role of L1 in the virion as a structural protein is clear, the role of L2 is less so, particularly 
with regards to immunogenicity. In natural infections, L2 plays roles in entry into the cell, entry into 
the nucleus, and assembly of the virion (reviewed in Pereira, 2008). The importance of L2 for the 
encapsidation of the plasmid of interest into PsVs has been well established, particularly in systems 
that rely on intracellular virion assembly (Rossi et al., 2000; Unckell et al., 1997). Several other 
studies have confirmed that while L1 alone is capable of packaging DNA, L2 vastly improves the 
packaging efficiency of DNA into PsVs (Kawana et al., 1998; Roden et al., 1996; Zhao et al., 1998). In 
comparison, Holmgren et al. (2004) showed that in true virus particles (produced by organotypic raft 
culture) L2 deficiency resulted in a 10-fold reduction in DNA encapsidation, as well as a 100-fold 
reduction in infectivity. There has been less agreement on whether L2 is required for virion entry 
into the cell, but it has recently been established that while L2 is not strictly required for infection, it 
greatly enhances the capacity of PsVs to transfer DNA (Peng et al., 2010). It has been shown that 
mutation of a single L2 cysteine residue involved intermolecular L2 disulphide bonds negatively 
affects infection of keratinocytes by inhibiting pseudovirion entry into the cell, while having no effect 
on assembly (Campos and Ozbun, 2009; Gambhira et al., 2009; Peng et al., 2011). This correlates 
with findings of Holmgren et al. (2004).  
 
Development of pseudovirions encapsidating a reporter plasmid has allowed for investigators to 
study the pseudoinfection of the mouse vaginal epithelia in vivo. This was achieved using HPV-16 
pseudovirions with a gene encoding a fluorescent protein, and has demonstrated that infection by 
PsVs closely mirrors infections by the natural virion. Vaginal infection occurs only after epithelial 
disruption, by either chemical or mechanical means. Following wounding of the epithelia, virions are 
deposited onto the basal membrane, and gene transfer into infected keratinocytes occurs as they 
migrate to begin wound repair (Graham et al., 2010; Roberts et al., 2007; Shi et al., 2001). Roberts et 
al. (2007) further demonstrated that L2 was required for successful infection of keratinocytes, and 
that no differentiated columnar epithelia were infected at any stage of the infection process. 
Notably, prior vaccination to HPV conferred complete protection against pseudovirion entry into 
cells in this study. 
 
Graham et al. (2010) demonstrated that intravaginal administration of PsVs resulted in transient, 















This is a clear difference to natural HPV infections, but is to be expected as HPVs have evolved 
complex mechanisms to avoid intracellular defence mechanisms. It has been suggested that vaginal 
administration of PsVs would be useful for delivery of short-term immunomodulatory genes, such as 
cytokines (Shi et al., 2001). 
 
It is clear that VLPs and PsVs very closely mimic the infectious properties of HPV due to their 
structural and behavioural similarities, particularly when both capsid proteins are incorporated. This 
results in comprehensive induction of the immune system. Several groups have confirmed that PsVs 
elicit a strong humoral and cellular immune response via both intravaginal and intramuscular 
administration (Oh et al., 2004; Shi et al., 2001; Zhang et al., 2004). This is likely mediated by binding 
and uptake by dendritic cells (DCs) - an important factor to the use of these particles as vaccines. 
DCs serve as the sentinels of the immune system, and delivery of antigens to these cells is a critical 
component of an effective vaccine (Lenz et al., 2001; Peng et al., 2010). In 2001, Lenz et al. showed 
that both L1 and L1+L2 VLPs are bound and internalised by DCs in vitro. This resulted in rapid 
phenotypic maturation of DCs and upregulation of major histocompatibility complex (MHC) class I 
and II proteins, cytokines such as Interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α), and 
induction of a strong Th1 response. This is a clear demonstration of the mechanisms behind the 
observed immune response to L1 VLP vaccination (Lenz et al., 2001; Yang et al., 2004). More 
recently, it was demonstrated that HPV PsVs are similarly bound and internalised by DCs, with a 
comparable immune response, and that the interaction with DCs is mediated by a toll-like receptor 
(TLR) pathway (Peng et al., 2010; Yang et al., 2004).  
 
It was established relatively early on that L1 VLPs elicited a strong neutralising antibody response, 
and this has been the basis for the development of current commercially available vaccines 
(Christensen et al., 1996b; Kirnbauer et al., 1996). L2 also elicits a neutralising antibody response - 
these antibodies are cross-neutralising for multiple HPV types (Campo et al., 1997; Chandrachud et 
al., 1995; Christensen et al., 1991; Embers et al., 2002; Gaukroger et al., 1996; Roden et al., 2000). 
However, Roden et al. (2000) demonstrated that when incorporated into L1+L2 VLPs, there was no 
cross-neutralising effect, and speculated that the L1 antibodies were immunodominant. It is likely 
that the lack of strong neutralising antibodies to L2 is due to the structure and composition of the 
virion: there are 5-30 times less L2 than L1 in a typical virion, and L2 is not naturally exposed until 
the virion undergoes conformational changes brought about by L1 binding to cell surface receptors 
















In conclusion, it is clear that we are moving towards a comprehensive model of infection and 
immune stimulation for these synthetic particles. This advanced level of understanding of HPV 
particle production and biology allows for several sophisticated applications of this technology, such 
as vaccine development.   
1.4. Applications of synthetic HPV particle technology 
 
Viral capsid assembly is efficient, genetically economical, energetically favourable, and reliable 
(Casini et al., 2004). These features make viral particles an extremely attractive option for the 
molecular packaging and delivery of various macromolecules, particularly DNA. Coupled with 
advances in protein fusion technology, recombinant viral particles represent almost unparalleled 
potential for preventative and therapeutic medicines. In recent times, HPV VLP vaccines have been 
successfully developed and commercialised, demonstrating the use of these particles in a medical 
context. 
1.4.1. Current HPV VLP vaccines 
 
HPV VLPs are an attractive vaccine candidate: they are stable, relatively straightforward to produce, 
and elicit strong immune responses. They are natural adjuvants, and stimulate both a B and T cell 
immune response (Lenz et al., 2001; Rudolf et al., 2001; Shi et al., 2001). Two prophylactic HPV VLP 
vaccines are commercially available, Gardasil® (Merck) and Cervarix™ (GlaxoSmithKline). Both 
vaccines are based on the HPV L1 capsid protein: Cervarix is a bivalent HPV-16/18 vaccine, while 
Gardasil is a quadrivalent vaccine that offers additional protection against the low-risk types HPV-6 
and -11 which cause genital warts (Lin et al., 2010). Both these vaccines are delivered by 
intramuscular injection, and elicit strong, type-specific neutralising antibody responses. These 
vaccines have both been shown to be safe, highly immunogenic and efficacious over the period that 
they have been available (reviewed in Stanley et al. (2008) and Mandic (2012)), with no evidence to 
suggest a loss of efficacy. While these vaccines are already showing early promise in easing the 
burden of cervical cancer in developed countries (Brotherton et al., 2011), the vaccines leave much 
to be desired with respect to breadth of type-specificity, prophylactic effect, cost, and ease of 
production (Kawana et al., 2009). Further, intramuscular administration of VLPs results in low 
mucosal immunogenicity (Oh et al., 2004). There are accordingly a number of efforts underway to 
















1.4.2. Use of HPV particles as gene delivery vehicles 
 
An emerging use for HPV PsVs is as biological gene delivery vehicles (GDVs). Delivery of medically 
relevant genes in vivo is a field with huge potential for the treatment of a large range of diseases and 
disorders. These include genetic deficiencies, cancers, and acute bacterial and viral infections. 
Further, they have the potential to revolutionise vaccine technology by providing effective delivery 
of DNA vaccines to cells. There are many aspects to consider when evaluating the effectiveness of a 
gene delivery vehicle. These include manufacturing feasibility, cost, stability, ease of storage and 
administration, replication competence, vector-specific toxicity, pre-existing vector immunity, tissue 
tropism, host range, and routes of administration (Graham et al., 2010). Currently, the most 
promising GDVs are viral vectors, such as adenoviral and lentiviral vectors, and synthetic liposomes. 
However, both of these systems have limitations, such as immune recognition, mutagenic 
integration, inflammatory toxicity and rapid clearance (Seow and Wood, 2009). 
 
 Pseudovirions represent an exciting new type of GDV. They are ideal for this purpose, as they 
represent the best of both viral and non-viral delivery systems. Gene delivery is efficient, as viruses 
have well-defined delivery and uptake mechanisms, and due to recent technological advances, PsVs 
are now easy to modify and produce (Lund et al., 2010; Seow and Wood, 2009). Further, there is no 
risk of reversion to live virus as no viral DNA is present. Apart from viral and non-viral DNA, 
pseudovirions can be utilised to encapsidate other non-viral cargos, such as small oligonucleotides, 
proteins, siRNA, organic polymers and fluorophores (Lu et al., 2012; Lund et al., 2010).  
1.4.3. HPV-based PsV candidate vaccines 
 
In the context of gene delivery, pseudovirions have particular promise as vaccines. These may be 
HPV vaccines, where the DNA could encode an additional antigen or adjuvant, or vaccine delivery 
vehicles for DNA vaccines of other viruses, where the HPV capsid serves merely as a GDV. There 
have been several promising early investigations into both of these possibilities. 
 
Pseudovirion vaccines represent aspects of several different types of vaccine, and early evidence 
suggests that this gives them significant advantages in terms of production and immunogenicity. Like 
VLPs and killed virus vaccines, they closely resemble the structural and behavioural characteristics of 
the native virion. Further, incorporation of plasmid DNA allows for stimulation of both humoral and 
cellular immunity, as seen in DNA vaccines (Gurunathan et al., 2000). Perhaps most importantly, 
















Various approaches to a pseudovirion vaccine have been tested in the last 10 years. These can be 
broadly divided into two groups – vaccines to HPV, which utilise the DNA-packaging capabilities to 
encode an adjuvant or additional epitopes (Combelas et al., 2010; Oh et al., 2004); and vaccines to 
other viruses, which utilise the immunostimulatory and gene transfer capabilities of PsVs to produce 
a more effective immune response to a DNA antigen (Gordon et al., 2012; Peng et al., 2010; Renoux 
et al., 2008; Shi et al., 2001; Zhang et al., 2004).  
 
Despite the success of the recently developed VLP vaccines (Cervarix and Gardasil), there remains 
some scope for improvement. The major downfall of these vaccines is the cost of production, low 
mucosal immunogenicity, and the limited cross-reactivity to other HPV types. To address the lack of 
mucosal immunogenicity, Oh et al. (2004) used L1 VLPs to encapsidate a gene encoding IL-2, to act 
as an adjuvant. They reported that IL-2 PsVs, delivered intramuscularly, induced the highest vaginal 
and salivary IgA response when compared to L1 VLPs, or L1 PsVs encapsidating an irrelevant plasmid, 
up to 6 weeks post-administration. They also demonstrated that encapsidation of an adjuvant 
plasmid was far more effective in eliciting an immune response when compared to co-delivery of 
VLP and plasmid. In a different approach, Combelas et al. (2010) encapsidated the HPV31 L2 gene 
into HPV58 L1+L2 VLPs, and used these PsVs to immunise mice. They demonstrated that PsVs 
elicited neutralising antibodies to HPV16, 18, 31, 58, demonstrating that including an L2 gene could 
improve on the range of cross-neutralising antibodies produced by HPV L1 or L1+L2 VLPs. One other 
interesting HPV vaccine candidate has been demonstrated for therapeutic cervical cancer treatment. 
This group packaged short hairpin RNAs (shRNAs) to E6 and E7 oncoproteins into HPV-31 PsVs. They 
showed that these PsVs effectively silenced E6 and E7 expression in cervical carcinoma cells, and 
dramatically inhibited cancer growth (Bousarghin et al., 2009).    
 
It is well known that the major limitation of DNA vaccines is inefficient delivery into cells (Graham et 
al., 2010). Recently, it has been extensively demonstrated that PsVs are significantly better at 
delivering DNA to cells than any other delivery method tested (Graham et al., 2010; Peng et al., 
2010; Renoux et al., 2008; Shi et al., 2001). This makes pseudovirions an attractive delivery system 
for DNA vaccine-expressed antigens. HPV PsVs are particularly attractive due to being mucosatropic 
viruses, which allows the possibility of inducing mucosal immunity, demonstrated as being key to 
controlling infection of viruses such as human immunodeficiency virus (HIV) and respiratory syncytial 
virus (RSV) (Graham et al., 2010). Accordingly, several groups have utilised the mucosatropic 















include simian immunodeficiency virus (SIV), HIV-1, RSV, and lymphocytic choriomeningitis (Gordon 
et al., 2012; Renoux et al., 2008; Shi et al., 2001; Zhang et al., 2004). Studies have also been 
performed using an HPV PsV carrying the model antigen gene, ovalbumin (OVA) (Peng et al., 2011; 
Peng et al., 2010). These studies used both intracellular assembly and in vitro disassembly-
reassembly methods to create the various HPV pseudovirions used, and most used L1+L2 PsVs. 
Subjects were immunised via oral, intramuscular or intravaginal delivery of pseudovirions. 
 
The most notable finding from these studies was the potent induction of a mucosal and systemic 
cytotoxic T-lymphocyte (CTL) response, which was seen in all cases. This is an important finding, 
particularly in the development of mucosal vaccines. A mucosal CTL response is critical in combatting 
mucosal infections, as many pathogens initiate infection in epithelial cells, before spreading to the 
rest of the body (Shi et al., 2001). The presence of CTLs and antibodies in the mucosa are required to 
regulate viral replications of diseases such as HIV (Zhang et al., 2004). Further, Zhang et al. (2004) 
and Graham et al. (2010) both showed a significant IgA induction, and demonstrated that oral or 
vaginal immunisation protected unrelated mucosae in the body from viral challenge. All studies 
showed induction of both a humoral and cellular immune response. 
 
The success of pseudovirions as vaccine delivery vehicles can be attributed to their ability to mimic a 
natural viral infection. This allows unprecedented induction of the immune system, and results in a 
holistic and highly immunogenic response to vaccination, regardless of the antigen in question (Peng 
et al., 2010). Another potentially valuable facet of PsVs is their stability. Shi et al. (2001) showed that 
PsVs were resistant to the low pH and proteolysis prevalent in the alimentary canal. This makes 
pseudovirions attractive for use in oral immunisation, and presents practically limitless scope for 
vaccines against orally tra smitted pathogens.  Further, the large number of HPV types and relatively 
low cross-reactivity between types makes HPV particles particularly attractive for DNA vaccine 
delivery as they allow repeated boosting without concern for prior immunity (Ma et al., 2011) 
1.4.4. Pseudovirion-based neutralisation assay (PBNA) 
 
It has long been recognised that neutralising antibodies confer lasting protection against 
papillomaviruses; this was first demonstrated for cottontail rabbit papillomavirus (Shope, 1937). 
VLPs, including the vaccines Gardasil and Cervarix, produce a strong neutralising antibody response, 
and the current assumption is that this is the mechanism of protection elicited (Schwarz and Leo, 
2008; Stanley, 2008). In 2000, Yeager et al. demonstrated a novel approach for the detection of 















neutralisation assay (PBNA). This group used an amine-to-sulfhydryl crosslinker (Sulfo-SMCC, Pierce) 
to attach a β-lactamase reporter gene to the exterior surface of HPV L1 + L2 VLPs produced in yeast 
cells to produce pseudovirions. They then treated mammalian cells with the pseudovirions, as well 
as sera from humans immunised with HPV-11 VLPs, and used fluorescence to identify those cells 
that were expressing β-lactamase. This technique has been further developed by Pastrana et al. 
(2004) and Steele et al. (2008) to utilise the ability of VLPs to encapsidate plasmid DNA. PBNA using 
pseudovirions carrying a Secretory Alkaline Phosphatase (SEAP) plasmid is now considered the gold 
standard for neutralisation assays, and is currently the best assay for efficacy of candidate 
prophylactic HPV vaccines (Buck et al., 2005a; Fleury et al., 2008b). Another group has also 
developed a neutralisation assay using a luciferase gene, although production efficacy is much lower 
(Fleury et al., 2008b). However, despite suggestions that the PBNA method espoused by these 
groups provides a high-throughput and practical method to evaluate antibody responses in both 
natural history and prophylactic vaccine studies (Pastrana et al., 2004), it remains expensive and 
time consuming, particularly for production of pseudovirions (Steele et al., 2008). Thus, alternative 
systems for pseudovirion production are attractive for both commercial and diagnostic applications. 
 
1.5. Plant production systems 
 
Over the last 20 years, transient and transgenic protein expression in plants has come of age, and 
now presents an attractive platform for the production of medically and industrially relevant 
proteins. At this stage, more than 100 different recombinant proteins have been expressed in plants; 
the list includes human serum proteins, growth regulators, antibodies, subunit vaccines, VLPs, 
industrial and commercial enzymes, and biopolymers (Schillberg et al., 2005; Tiwari et al., 2009). 
Further, the regulatory framework has now been put in place to allow for commercial applications of 
this technology (Rybicki, 2010). 
 
1.5.1. Transient expression as an alternative to transgenic plant production 
 
Historically, proteins produced in planta have suffered from low yield, poor and inconsistent quality, 
and a lack of framework for good manufacturing practice (GMP) (Schillberg et al., 2005; Streatfield 
and Howard, 2003). Reliance on transgenic protein expression resulted in poor or uncertain yields, 
and long timeframes for development of a product. Furthermore, several biosafety incidents (such 















plant production systems for commercial and medical applications (Huang et al., 2009; Rybicki, 
2010). More recently, however, transient expression of proteins has become an increasingly feasible 
alternative to stable transformation of plants, and now appears to be a superior approach to protein 
production.  
 
Transient expression of proteins in plants can be executed in two ways: by utilising viral vectors such 
as those derived from tobacco mosaic virus (TMV) or potato virus X (PVX), or by agroinfiltration of a 
plant expression construct into the plant. Viral vectors showed great promise as their action is both 
rapid and systemic (Schillberg et al., 2005). However, administration can be difficult, particularly in 
the case of RNA viral vectors, and there has been demonstrated loss of the transgene due to 
impaired fitness (Rybicki, 2010). Agroinfiltration of viral and non-viral vectors is considered a viable 
alternative to the use of viral vectors alone, as it allows easier administration, with similar rapid and 
systemic transgene induction, and without the gene size restraints of traditional viral vectors (Kapila 
et al., 1997). Originally developed for protein expression in plants recalcitrant for stable 
transformation, agroinfiltration utilises the DNA transfer behaviour of the infectious bacterium 
Agrobacterium tumefaciens to induce systemic production of a protein of interest (Kapila et al., 
1997). Transient expression is favourable to the establishment of transgenic lines, as it is much 
quicker (3-9 months for transgenic vs. days for transient expression), shows much higher protein 
yields, is more amenable to scale-up and GMP, and is much easier to contain (Rybicki, 2010; 
Schillberg et al., 2005; Tiwari et al., 2009). Agroinfiltration was previously thought to be useful only 
for testing of gene expression before using more traditional approaches to transform plants (Fischer 
et al., 2004). However, co-infiltration with viral silencing suppressors and the development of 
industrial-scale vacuum infiltration operations has shown transient expression to be a highly 
effective tool for large scale production of recombinant protein (D'Aoust et al., 2008). 
 
Of particular interest in our laboratory is the use of replicating DNA viral vectors for transient 
expression. This technology utilises small ssDNA viruses of the family Geminiviridae to create 
deconstructed viral vectors which replicate to high copy numbers when introduced into plants by 
agroinfiltration. Geminiviruses in the genus Mastrevirus commonly encode only four proteins, 
namely coat protein (CP), movement protein (MP), and the replication-associated protein Rep and 
RepA (Liu et al., 1997). Rep and RepA are the only viral components required for replication, which 
occurs by a rolling circle mechanism and amplifies the circular genome to high copy number (Huang 
et al., 2009). While early applications simply replaced the CP with a gene of interest (Kammann et 















namely the genes encoding Rep/RepA, and two intergenic regions which contain regulatory 
elements (Mor et al., 2003). These genetic elements maybe supplied on two or more co-infiltrated 
vectors (Hefferon and Fan, 2004; Mor et al., 2003; Zhang and Mason, 2006), or on a single vector 
(Huang et al., 2009; Regnard et al., 2010; Tamilselvi et al., 2004). These recent advances have shown 
that the incorporation of geminiviral genetic elements into viral vectors is a successful strategy for 
replication to high copy number and subsequently high protein production (Hefferon, 2012).  
 
In addition to the improvements brought about by transient expression technology, several inherent 
properties of plants make this system appealing. Recombinant proteins are faithfully expressed in 
plants: they have also been shown to retain the correct size, as well as tertiary and quaternary 
structure, and are post-translationally processed similarly to mammalian cells. Plants as a production 
system represent the possibility of rapid and affordable scale-up to industrial scales, as well as a 
reduced raw material cost, when compared to other eukaryotic or bacterial production systems. 
Further, they pose no risk of contamination with human or animal pathogens (Streatfield and 
Howard, 2003; Thanavala et al., 2006). Many crop species have been used for transgenic and 
transient production. While protein expression levels have shown to be broadly similar across the 
many species tested, Nicotiana spp. have risen to the forefront of recombinant protein production, 
due to their high yield, strong biosafety profile, non-feed/non-food crop status, and rapid scalability 
(Fischer et al., 2004; Schillberg et al., 2005). 
 
In conclusion, transient protein expression in plants is clearly an effective tool for small- and large-
scale production of protein.  With the current improvements in technology and regulatory 
framework, plant production offers a scalable and affordable way to increase production capacity to 
meet rising global demand for recombinant proteins (Fischer 2004). In particular, this is appealing 
for medical applications. 
1.5.2. Antigen production in plants  
 
In 1989, Hiatt et al. produced fully assembled and functional monoclonal mouse antibodies in 
transgenic tobacco (Hiatt et al., 1989). Following this first successful demonstration of medically 
relevant protein expression in planta, another group produced the first antigen in plants – Hepatitis 
B surface antigen (HBsAg) – and observed that the protein produced was structurally and 
antigenically similar to serum-derived HBsAg. Further, they showed that these protein subunits 
assembled to form particles (Mason et al., 1992). Soon after, Haq et al. (1995) showed that plant-















mice, and generated neutralising antibodies. Since that time, many different antigens have been 
produced by both transgenic and transient expression, from a broad range of human and animal 
diseases. Importantly, it has been conclusively demonstrated that antigens produced in plants 
assemble efficiently and are capable of eliciting a strong, antigen-specific B- and T-cell response 
(Streatfield and Howard, 2003). There are several plant-produced antigens currently in clinical trials 
(Reviewed in Tiwari et al. (2009). Further, several plant-produced products are licensed. These 
include an antibody used for recombinant Hepatitis B virus HBV vaccine production (Pujol et al., 
2005), and a Newcastle disease virus (NDV) vaccine for chickens (Rybicki, 2009). 
1.5.3. HPV vaccine development in plants 
 
Several groups have expressed HPV proteins in plants, by both transient and transgenic expression 
methods. The oncogenic E7 protein was expressed using a PVX-derived viral vector, and induced 
cellular and humoral immunity, as well protecting mice against tumour challenge (Franconi et al., 
2002). Several groups produced L1 in transgenic plants, and observed that VLPs assembled in planta 
with varying degrees of efficiency (Biemelt et al., 2003; Liu et al., 2005; Varsani et al., 2003; 
Warzecha et al., 2003). These groups also showed that VLPs produced were morphologically similar 
to VLPs produced in non-plant systems, and that they elicited a similar immunological response. 
While this was a promising step for the production of a vaccine candidate in plants, yields were 
extremely low (<0.5% of total soluble protein (TSP)).  
 
The first demonstration of protection elicited by plant-produced papillomavirus capsid protein 
followed shortly after. Kohl et al. (2006) showed that transgenic-plant-produced cottontail rabbit 
papillomavirus L1 protein conferred protective immunity against challenge by live virus. While they 
demonstrated low neutralising antibody responses, and no VLP formation, this was an important 
step toward HPV vaccine production in plants. Subsequently, Varsani et al. (2006) used a TMV-
derived vector to transiently express L1 in tobacco. This resulted in an approximate 10-fold increase 
in protein expression compared to transgenic production, but low immunogenicity, which the 
authors ascribed to an overabundance of L1 subunit proteins relative to capsomeres and assembled 
VLPs. Soon after, the same group performed a thorough comparison of various codon-optimisation 
and cellular localisation strategies for increased expression of HPV16 L1, using agroinfiltration of a 
cauliflower mosaic virus-derived plasmid.  The authors reported L1 expression at approximately 17% 
of TSP, using a human codon-optimised gene and a chloroplast localisation signal (Maclean et al., 
2007). Other investigators have shown similar high expression of L1 in the chloroplast, although this 















Maclean et al. (2007) further showed that L1 VLPs produced this way were highly immunogenic, and 
induced a strong neutralising antibody response. 
1.6. Objectives of the work 
 
In this project, I set out to to manufacture plant-produced HPV-16 pseudovirions for use in the 
pseudovirion-based neutralisation assay, with a view to developing a cheaper alternative to the 
current assay approach. To achieve this, I aimed to modify the previously developed Bean yellow 
dwarf mastrevirus (BeYDV)-derived pRIC3 vector plasmid to provide the reporter gene plasmid 
required for the PBNA, and use HPV-16 L1 and L2 proteins to form the pseudovirion protein shell, or 
capsid. Specifically, the objectives of the project were to: 
1) Design and construct three novel replicating vectors to be encapsidated in L1+L2 PsVs 
2) Express and purify HPV-16 pseudovirions in N. benthamiana 
3) Use these plant-produced pseudovirions in a successful neutralisation assay in mammalian 
cells 
To achieve the first objective, I needed to create three novel replicating vectors. These were to be 
modified from pRIC3, an autonomously replicating shuttle vector developed in our laboratory 
(Regnard et al., 2010), to include two different mammalian expression cassettes. The entire 
expression cassette was taken unchanged from the pYSEAP vector developed by Pastrana et al. 
(2004). The second was taken from the pTH plasmid originally developed by Hanke et al. (1998), and 
further modified by Tanzer et al. (2011), and modified to carry the luc reporter gene. 
 
The second objective was to use these plasmids, along with non-replicating plant vectors expressing 
human codon-optimised L1 and L2, to produce PsVs in plants. Autonomous replication of the pRIC3 
vectors would be expected to result in approximately 5-7.5Kbp replicons, a size able to be packaged 
by assembling HPV virions, made up of the co-expressed L1 and L2 proteins. These PsVs would be 
purified and tested for DNA encapsidation. 
 
The third objective was to demonstrate the infectivity of plant-produced PsVs in a mammalian cell 
culture system. To this end, particles would be purified and used to infect mammalian cells. 
Successful infection would result in expression of SEAP or luciferase. Lastly, these PsVs would be pre-

















Chapter 2: Construction and testing of replicating vectors for 
pseudogenome production 
2.1. Introduction  
 
This study aimed to produce PsVs in planta, to be used for pseudoinfection of mammalian cells with 
a pseudogenome carrying a mammalian reporter gene. To achieve this, autonomously replicating 
viral vectors were identified as promising candidates for pseudogenome production. In particular, 
geminivirus-derived vectors were selected for their small plasmid size and rapid and consistent 
replication to high copy number in plants. Other genetic elements utilised for production of the 
pseudogenome include two mammalian reporter gene cassettes for the expression of luc or SEAP, as 
well as a novel mammalian enhancer element. The newly created replicating vectors were tested for 
reporter gene expression by transfection of mammalian cells. 
2.1.1. Modification of geminiviruses for use as vectors  
 
Single-stranded DNA (ssDNA) plant viruses have recently been utilised as vectors for transient 
expression of proteins at high volume (Hefferon and Fan, 2004; Mor et al., 2003; Regnard et al., 
2010). ssDNA viruses are some of the most widely distributed of all the viruses, infecting prokaryote, 
plant and animal hosts. The smallest of these are in the Geminiviridae, Nanoviridae, and Circoviridae 
families. The first two consist of plant viruses, the third of avian and mammalian viruses. These 
viruses show an organisation characterised by divergent ORFs and highly compact, ambisense 
genomes - overlapping promoter and ori sequences, and promoter sequences within ORFs, are 
common (Liu et al., 1998; Mankertz and Hillenbrand, 2002). The two elements that remain 
consistent in the genomes of these viruses are ORFs that code for 1) a replication-associated protein 
complex (Rep/RepA) that recruits cellular machinery and initiates replication via the rolling circle 
replication (RCR) model, and 2) a coat protein (CP) which pentamerises to form the units of the viral 
capsid.  
 
Geminiviruses, which infect plant host cells,  are the simplest of the Geminiviridae (Stanley, 1993). 
They are unique amongst the viruses in that they have a geminate capsid structure, made up of two 
partially assembled capsids (Zhang et al., 2001). One geminivirus in particular, the Bean yellow dwarf 
virus (BeYDV), has been well characterised, and is an attractive target for vector development 
(Halley-Stott et al., 2007). This virus is made up of four transcribed ORFs - V1 and V2 (on the virion 















complementary-sense strand code for Rep and RepA – as well as short and long intergenic regions 
(SIR and LIR) (See Fig. 2.1). The movement protein ORF, V1, shows sequence homology with maize 
streak virus V1, the product of which is responsible for virus movement. The coat protein, once 
expressed, pentamerises to form the viral capsid. The proteins Rep and RepA are responsible for 
initiating replication in the host cell, as described earlier. The LIR contains promoter elements and 
the viral double-stranded ori, while the SIR contains the transcription termination signal and primer 
binding sites for C-strand DNA synthesis. Like all geminiviruses, it replicates via the RCR cruciform 
model, a version of the RCR model which includes the formation of a cruciform, or stem-loop 
structure at the double-stranded origin of replication, in the LIR.  
 
BeYDV has been modified for use as an Agrobacterium-mediated plant expression vector by several 
groups (Hefferon and Fan, 2004; Mor et al., 2003; Regnard et al., 2010; Zhang and Mason, 2006). 
While Zhang and Mason (2006) use the BeYDV replicon to achieve a stable transfection of Solanum 
tuberosum, Regnard et al. (2010) has modified the BeYDV for transient, high level expression, using 
Figure 2.1 | Organization of the BeYDV genome The arrangement of virion-sense (V) and complementary-sense (C) ORFs 
with the potential to encode proteins in excess of 10 kDa molecular mass are shown relative to the large and small 
intergenic regions (LIR and SIR, respectively). Shaded ORFs are those that are conserved between BeYDV subgroup I 
members - V1, movement protein; V2, coat protein; C1, Rep; C2, RepA. Removal of the intron (nucleotides 1722–1807, 
indicated by lines) serves to fuse ORFs C1 and C2 (ORF C1C2, from which Rep is produced), and ORFs C4 and C1 (ORF C4C1, 
found only in BeYDV and Tomato Yellow Dwarf Virus (TYDV)). PstI and ClaI are restriction enzyme sites. Reproduced from Liu 















Nicotiana benthamiana. To achieve this high level expression, Regnard et al. (2010) replaced the 
ORFs for the CP and MP with a cauliflower mosaic virus (CaMV) 35S promoter (with duplicated 
transcriptional enhancer sequence), multiple cloning site (MCS), and polyadenylation signal, as well 
as a duplicate copy of the LIR. Notably, the introduction of an additional LIR into the vector allows 
for the formation of a circular replicon within the plant host cell. This duplication is a common 
feature of all replicating plant expression vectors (Regnard et al., 2010). The two LIR sequences are 
located within the left and right border sequences (LB and RB, Figure 2.2), which enclose the transfer 
DNA (T-DNA), that part of the vector that is transferred into plants during agroinfiltration (Zupan et 
al., 2000). Two LIR copies allows for the formation of the active, circularised dsDNA replicon in plants 
after T-DNA delivery to the plant cell. This circular form is integral to the cruciform RCR model – the 
cruciform structure formed by the LIR is the recognition and binding site for the Rep/RepA protein 
complex (Khan, 2005). Once this complex is formed, the recircularised plasmid, or replicon, forms a 
double-stranded DNA intermediate, which is replicated to high copy number in the cell. 
 
This replicating vector, designated pRIC, has demonstrated high replication in planta (up to two 
orders of magnitude greater than a highly expressed, non-replicating vector, pTRAc) and thus high 
protein expression – 3-7 fold higher than pTRAc over a seven-day time trial using transgenes 
encoding enhanced green fluorescent protein (EGFP), or subunit antigens (HPV-16 L1 and HIV C p24), 
inserted at the MCS (Regnard et al., 2010). While these constructs showed high protein expression 
Figure 2.2 | 2nd generation vector pRIC3 and replicon ColE1 ori, origin of replication for Escherichia coli; RK2 ori, origin of 
replication for Agrobacterium tumefaciens; bla, ampicillin⁄carbenicillin resistance bla gene; LB and RB, left and right borders 
for T-DNA integration; P35SS, CaMV 35S promoter with duplicated transcriptional enhancer; CHS, chalcone synthase 5`-
untranslated region; MCS, multiple cloning site, pA35S, CaMV 35S polyadenylation signal; LIR, BeYDV long intergenic region; 
SIR, BeYDV short intergenic region; rep, BeYDV rep gene. The grey bar inside the plasmid maps indicates the T-DNA 















compared to a similar, non-replicating vector, concerns remain that duplicated structures may lead 
to recombination (Regnard et al., 2010). This instigated the development of 2nd-generation vectors, 
by removal of the two scaffolding regions, the polyadenylation signal pA35S, and one of the two 
CaMV promoter sequences, resulting in the vector shown in Fig. 2.2. This vector, designated pRIC3, 
was demonstrated to have similar levels of replication to pRIC, as determined by qPCR, and showed 
higher protein expression at 1 and 3 days post infiltration (dpi) (Ogle, 2008).  
 
Both of these vectors (pRIC and pRIC3) have demonstrated replicational release (formation of the 
circularised replicon) once they are within the plant cell host, which allows high-copy number 
replication. This autonomous replication makes pRIC3 an ideal vector for the production of 
pseudogenome DNA in plants. Insertion of a mammalian promoter, reporter gene, and 
polyadenylation signal elements (collectively referred to as a cassette) into pRIC3 within the T-DNA 
will result in replication to high copy number of a replicon incorporating a mammalian reporter 
cassette. This replicon will be used as a mammalian reporter pseudogenome, which should then be 
packaged by HPV capsid proteins in planta to form PsVs. To further optimise mammalian reporter 
gene expression we included an enhancer element from porcine circovirus (PCV), which has recently 
been shown to increase expression of a mammalian gene (Tanzer et al., 2011).  
2.1.2. Porcine circovirus  
 
Porcine Circovirus (PCV) is an ssDNA virus of the family Circoviridae, which is comprised of viruses 
such as PCV, beak and feather disease virus and goose circovirus (Finsterbusch and Mankertz, 2009). 
Circoviruses are single-stranded, circular and non-enveloped viruses, with a size of approximately 
1760bp (Tischer et al., 1982), making them the smallest known autonomously replicating 
mammalian viruses (Mankertz et al., 1998). There are two PCV strains identified, PCV-1 and PCV-2. 
PCV-1 is non-pathogenic (Tischer et al., 1995), while PCV-2 is the etiological agent in the porcine 
disease post-weaning multisystemic wasting syndrome (PMWS). Like geminiviruses, PCV-1 is made 
up of two major ORFs, rep and cap, which code for the Rep protein and the capsid protein, 
respectively. These are arranged in an ambisense fashion, with the intergenic region between the 5’ 
ends encoding the viral Ori, as well as the rep promoter element, Prep. The promoter for cap (Pcap) 
















This simple and extremely compact genome makes PCV-1 a good potential source of mammalian 
plasmid vector elements. Fiona Tanzer, an investigator in this lab, developed a vector for use as a 
potential HIV DNA vaccine. To achieve this, she inserted elements from the PCV-1 genome into the 
DNA vaccine plasmid vector pTHgrttnC. Developed by Hanke (Hanke et al., 1998; Mankertz et al., 
1998), this vector was created by removing the neomycin resistance gene and the f1-M13 ori from 
pRc/CMV (Invitrogen™), then substituting the CMV enhancer/promoter region for a cytomegalovirus 
enhancer/promoter/intron region. This was further modified into a DNA vaccine, pTHgrttnC by this 
group and another, the Williamson group at IIDMM (Burgers et al., 2006), by the insertion of the 
recombinant HIV gene, grttnC. The vector-based vaccine used by Tanzer was created from this. The 
core and conserved late element (CLE) of the PCV-1 Cap promoter region (Pcap) was sub-cloned 
immediately adjacent to the CMV i/e promoter region of pTHgrttnC, to form pTHpCapRgrttnC. In the 
current work, the mammalian promoter, enhancer and polyadenylation signal elements from the 
pTHpCapRgrttnC construct were used for one of the mammalian cassettes introduced into pRIC3. 
2.1.3. Reporter genes and cost of assay 
 
Selection of mammalian reporter cassettes is an important aspect of vector construction. Genes for 
several reporter proteins have been packaged into PsVs produced in mammalian cells – these 
include luciferase (luc), β-galactosidase, Secreted Alkaline Phosphatase (SEAP) and puromycin 
resistance gene (pac) (Buck et al., 2005a; Stauffer et al., 1998; Touze and Coursaget, 1998; Unckell et 
al., 1997). In recent years, SEAP has become the standard reporter gene used for PBNA, as originally 
demonstrated by Buck et al. (2005a). While this assay has been shown to be effective for PBNA, it is 
one of the most expensive reporter assays available (R36.63/reaction). Luciferase assays, on the 
other hand, are much cheaper (R16.33/reaction), and have been used for PBNA, though with lower 
efficiency (Fleury et al., 2008a). Accordingly, both SEAP and luciferase cassettes were selected for 
Figure 2.3 | Consensus PCV genome showing ORFs and promoter regions The 172bp Pcap region shown has been used 















testing. In the reporter plasmid pYSEAP, the SEAP reporter gene is under control of the elongation 
factor 1 alpha (EF-1α) promoter and the simian virus 40 (SV40) polyadenylation signal, while 
luciferase is under control of the mammalian expression cassette from the pTH expression plasmid. 
This is made up of the cytomegalovirus (CMV) intron/enhancer/promoter element with the addition 
of pCapR enhancer region, and the bovine growth hormone (BGH) polyadenylation signal. Both 
these cassettes have been extensively utilised for constitutive, high level expression in mammalian 
cells (Buck et al., 2005a; Burgers et al., 2006; Tanzer et al., 2011). 
 
The aim of this study was to adapt the previously developed geminivirus-derived pRIC3 vector to 
produce three replicating vectors, which would replicate in planta to form pseudogenomes for 
packaging by HPV L1 and L2 capsid proteins into PsVs. Two different mammalian expression 
cassettes were chosen, encoding genes for the reporter gene products SEAP (mSEAP cassette) and 
luc (mluc cassette). Both mammalian cassettes were incorporated into pRIC3 with the extant plant 
cassette (+) serving to increase the overall replicon size (pRIC3-mSEAP+ and pRIC3-mluc+), while the 
SEAP cassette was also incorporated in place of the plant cassette to create a smaller replicon 
(pRIC3-mSEAP). HPV VLPs have been reported to package pseudogenomes of approximately 5-8Kbp 
in size, whereas larger or smaller pseudogenomes are not packaged at all (Buck et al., 2004; Touze 
and Coursaget, 1998). To accommodate these size constraints, three vectors were created with 
different reporter genes and resulting in replicons of different sizes: 
 
a) pRIC3-mSEAP – pRIC3 with a mammalian cassette encoding the SEAP reporter gene in place 
of the current plant cassette (4.8Kbp replicon/pseudogenome) 
b) pRIC3-mSEAP+ – pRIC3 with the addition of a mammalian SEAP cassette, inserted upstream 
of the plant cassette (6.6Kbp replicon/pseudogenome) 
c) pRIC3-mluc+ - pRIC3 with the addition of an alternative mammalian cassette encoding the 
















2.2. Materials and Methods 
2.2.1. Cloning strategy 
 
 The previously created pRIC3 (Figure 2.2) will be further developed into three distinct autonomously 
replicating vectors (See Figure 2.4), for infiltration into plants. To achieve the aims of this project, 
several modifications of the previously described plasmid pRIC3 were required. These modifications 
resulted in three final plasmids, shown in Fig. 2.4. These were named pRIC3-mSEAP, pRIC3-mSEAP+, 
and pRIC3-mluc+. The final plasmids retained most of the original features of pRIC3, differing only in 
the expression cassettes found on the replicon. A simplified workflow is shown in Fig. 2.5, detailing 
the major steps in construction of these plasmids. 
2.2.1.1. Modification of pRIC3 to generate pRIC3.2 
 
The backbone used for the constructed plasmids, pRIC3, is a plasmid that has been in development 
for some time as an autonomously replicating plant vector in this laboratory (Regnard et al., 2010). 
This plasmid was modified by the re-introduction of SalI and XhoI sites, at the 5’ and 3’ ends of the 
plant expression cassette of pRIC3, respectively (Figure 2.5B). This allowed for ligation of the entire 
mammalian cassette upstream of the plant cassette. These sites were used in the original 
construction of the pRIC vector, but were destroyed during cloning. As such, at each site a single 
nucleotide mutation was required to restore the recognition sequences – G>C for SalI, and C>G for 
XhoI.  
Vector Insert Vector Size (Kbp) Replicon Size (Kbp) 
pRIC3 Plant cassette 6.6 3.5 
pRIC3-mSEAP SEAP cassette 7.9 4.8 
pRIC3-mSEAP+ SEAP and plant cassettes 9.7 6.4 


























































This was achieved via an application of PCR referred to as overlap extension PCR (OE-PCR), first 
described by Higuchi et al. (1988) (See Figure 2.6). Briefly, forward and reverse primers were 
designed incorporating the region of the plasmid which contained the destroyed restriction sites, 
with the appropriate single nucleotide mutation (B and C, Table 2.1, mutation shown in red). A 
corresponding primer was designed for each (A and D), such that two PCR amplification products, 
fragment I and fragment II, were generated (See Figure 2.6 and Table 2.2). Each of these fragments 












































Figure 2.5 | Simplified Cloning Strategy A simplified workflow for cloning of three autonomously replicating 
vectors used in this study. (A) Creation of SEAP mammalian cassette (mSEAP). (B) Restoration of SalI and XhoI 
restriction enzyme sites in pRIC3. (C) Creation of luc mammalian cassette. (D) Final replicating vector construction. 





















fragment I included a BglI site at the 5’ end of the fragment, while fragment II included an EcoRV site 
at the 3’ end of the fragment. After the amplification of fragments I and II, a second PCR, using 
primers A and D, and with both fragments I and II as template, was performed, resulting in the 
amplification product pR3fr-M (reaction 5, table 2.2). This fragment was bounded by a 5’ BglI site 
and a 3’ EcoRV site, and identical to the original sequence, except for the introduced single 
nucleotide mutation which restored the SalI restriction site. Sequence analysis was used to confirm 
that the correct sequences were generated. An identical process was used for the introduction of 
XhoI into pRIC3 (Primers E, F, G, and H, Table 2.1; reactions 3, 4, and 6, Table 2.2; amplification 
products III, IV and pR3fr2-M, Figure 2.6 and Table 2.2). The restriction enzyme sites utilised to ligate 
pR3fr2-M into pRIC3 to yield pRIC3.1 were BamHI at the 5’ end of fragment III, and XbaI at the 3’ end 
of fragment IV. After restriction enzyme digestion, products were separated on a 1% TBE agarose 
gel, visualised using a 365nm UV lightbox, excised, and purified using the Biospin Gel Extraction Kit 
(Bioer Technology Co. Ltd.). Purified products were then ligated using the T4 DNA ligase kit (Roche), 
and ligated at 4° C overnight. Electrocompetent E.cloni® cells (Lucigen) were transformed with 5ul of 


































Figure 2.6 |OE-PCR scheme for restriction site rescue Diagram showing all relevant elements involved in 
restoration of SalI and XhoI sites in pRIC3. Blue lines indicatePCR fragments with introduced mutations. Red 
lines indicate full-length fragments cloned into pRIC3. All relevant fragments are indicated. Introduced 















ice for 2 minutes. 500µl of antibiotic-free media (luria broth) was then added to the cells, and they 
were incubated at 37° C for 1 hour and grown under ampicillin selection (50µg/ml). Colony PCR 
(reaction 5, Table 2.2) was used to screen for positive pRIC3.1 colonies. To form pRIC3.2, pRIC3.1 and 
pR3fr-M were both digested with BglI and EcoRV and ligated as previously described. Colonies were 
screened for recombinant pRIC3.2 clones by colony PCR (Table 2.2, reaction 11), and plasmid DNA 
was extracted for confirmation of successful ligation by restriction digest and sequencing analysis, to 
yield pRIC3.2.  
2.2.1.2 Cloning of mammalian cassettes for ligation into pRIC3.2 
 
The mammalian expression cassettes utilised in vector construction were obtained from a variety of 
sources. All genes are commercially available as part of reporter plasmids or well-developed assays. 
The luciferase (luc) gene came from the commercial pGL3-promoter plasmid, from Promega. The 
secreted alkaline phosphatase (SEAP) gene was taken from the pYSEAP plasmid, used for 
neutralisation assays in mammalian cells, and originally developed by Pastrana et al. (2004). The 
pTHpCapRgrttnC plasmid was taken from a study by Tanzer et al. (2011), who showed that the 
enhancer region pCap, inserted into the promoter region in the reverse orientation, enhanced 
expression of the gene of interest. This expression vector was originally developed by Hanke et al. 
(1998). 
 
The entire SEAP expression cassette was cloned directly from the vector pYSEAP (see Figure 2.5A). 
This vector, developed for use in PBNA, carries the SEAP gene under the control of the EF1alpha 
constitutive promoter element for high-level expression in mammalian cells. PCR was performed to 
amplify the 3069bp cassette, and introduce a SalI site at the 3’ end for cloning into pRIC3.2 (the 
cassette also incorporated another existent SalI site at the 5’ end, which was used for later cloning) 
using primers SEAPSal-F and SEAP-R (3075bp; reaction 7, Table 2.2).  
 
To create the mluc cassette, luciferase was cloned into the pTHpCapR vector, replacing the grttnC 
polyprotein, to incorporate the pCapR enhancer element (see Figure 2.5C). The luciferase gene luc 
was excised from the commercial reporter plasmid pGL3-promoter by HindIII and EcoRI restriction 
enzyme digestion. The products were separated by gel electrophoresis on a 1% agarose TBE gel and 
visualised on a longwave (365nm) UV lightbox. DNA was excised and purified using as previously. 
The pTHpCapRgrttnC vector was similarly digested and purified. The luc gene was ligated into 
pTHpCapRgrttnC in place of the grttnC polyprotein. PCR was performed to amplify the newly created 















expression vector pTHpCapRluc (reaction 8, Table 2.2). The PCR product was purified as previously 
and cloned into the commercial blunt-end ligation vector pJET1/blunt (Promega), to form the 
intermediary vector pJET-mluc. 
2.2.1.3. Cloning of mammalian cassettes into pRIC3.2 to generate pRIC3-mSEAP, pRIC3-
mSEAP+, and pRIC3-mluc+ 
 
The regeneration of SalI and XhoI sites created the intermediate pRIC3.2, and allowed for serial 
cloning of the mammalian expression cassettes mluc and mSEAP into the pRIC3.2 plasmid. To create 
pRIC3-mSEAP (Figure 2.7A), the mammalian cassette was digested with and SalI, and pRIC3.2 was 
B 
Figure 2.7 | Construction of pRIC3-mSEAP and replicon Autonomously replicating plasmid pRIC3-mSEAP. (A) Final 
cloning steps to create pRIC3-mSEAP. (B) EF-1α, elongation factor 1 alpha promoter; SEAP, Secreted Alkaline 
Phosphatase gene; SV40 PolyA, simian virus 40 polyadenylation signal. Grey elements remain unchanged from 
the original pRIC3 vector; mammalian cassette highlighted in coloured regions. White bar inside plasmid map 
































































digested at the newly regenerated SalI and XhoI sites. The two digested fragments (i.e. the mSEAP 
cassette and the pRIC3.2 vector missing the plant cassette) were gel purified as previously, and 
ligated. Colony PCR was used to screen for positive clones, and positives were chosen for 
confirmation by plasmid mapping and sequence analysis (See Figure 2.7B and C).To generate pRIC3-
mSEAP+ (See Figure 2.8A), pRIC3.2 was digested with SalI only, resulting in linearization of pRIC3.2. 
The mSEAP cassette was digested with SalI as previously, and the resulting products were purified 




























Figure 2.8 | Construction of pRIC3-mSEAP+ and replicon pRIC3-mSEAP+ autonomously replicating plasmid . (A) 
Final cloning steps in consgtruction of pRIC3-mSEAP+. (B) EF-1α, elongation factor 1 alpha promoter; SEAP, 
Secreted Alkaline Phosphatase gene; SV40 PolyA, simian virus 40 polyadenylation signal; CaMV 35S, cauliflower 
mosaic virus promoter region, EGFP, enhanced green fluorescent protein gene; pA35SS, CaMV 35S 
polyadenylation signal. Grey elements remain unchanged from the original pRIC3 vector; mammalian and plant 
cassettes highlighted in coloured regions. White bar inside plasmid map indicates T-DNA transfected into plant 



















































mammalian and plant cassette (See Figure 2.8B and C).Generation of pRIC3-mluc+ was performed in 
a similar manner to pRIC3-mSEAP+ (Figure 2.9A). The intermediate pJET-mluc was digested with SalI 
and XhoI to excise the mammalian cassette from the pJET1/blunt vector backbone. pRIC3.2 was 
linearised by digestion with SalI only. Products were purified, ligated and screened as previously, 



















Figure 2.9 | Construction of pRIC3-mluc+ and replicon Autonomously replicating plasmid pRIC3-mluc+. (A) Final 
cloning steps to create pRIC3-mluc+. (B)CMV I/E/P + pCapR, cytomegalovirus intron/enhancer/promoter region 
with pCapR enhancer; luc, firefly luciferase reporter gene; BGH polyA, bovine growth hormone polyadenylation 
signal. CaMV 35S, cauliflower mosaic virus promoter region, EGFP, enhanced green fluorescent protein; pA35SS, 
CaMV 35S polyadenylation signal. Grey elements remain unchanged from the original pRIC3 vector; mammalian 
and plant cassettes highlighted in coloured regions. White bar inside plasmid map indicates T-DNA transfected into 









































2.2.2. PCR and Primer Design 
 
 Several applications of PCR were used in this study. All primers used are shown in Table 2.1, and the 
various PCR reactions are shown in Table 2.2. Polymerase chain reactions 1-7 were performed using 
ACCUZYME™ Polymerase (Bioline), a high fidelity proofreading polymerase, under the following 
conditions: 95°C for 3 minutes; 25 cycles of 95°C for 30”, variable annealing temperature for 30”, 
68°C for 1-3 minutes; and 68°C for 5 minutes. PCR reaction 8 was performed using the high fidelity 
Pfu DNA Polymerase (Fermentas), under the conditions outlined below. All other PCRs were 
performed using the GoTaq Kit (Promega), under the following conditions: 95°C for 3 minutes; 25 
cycles of 95°C for 30”, variable annealing temperature for 30”, 72°C for 1-3 minutes; and 72°C for 5 
minutes. Annealing temperature and Mg2+ concentration are indicated on Table 2.2 for each 
reaction. 
 
Table 2.1 | Primers designed and utilised in this project Nucleotide changes are shown in red.  
Name Primer Orientation 
A 5'-CTCGGCCCTTCCGGCTGGCTGG-3' F 
B 5'-CAGGTCGACCAAATACCATCACATCG-3' R 
C 5'-GATGTGATGGTATTTGGTCGACCTGG-3' F 
D 5'-CCCTTACGTCAGTGGAGATATCACATC-3' R 
E 5'-ACGCTCTAGAGTCCGCAAAAATCACC-3' F 
F 5'-TCGCTCGAGCCGCCGCCCGGTC-3' R 
G 5'-ACCGGGCGGCGGCTCGAGAATG-3' F 
H 5'-GGTGGGATCCCTTCTATAATTCTTTGC-3' R 
pJET-F 5'-GCCTGAACACCATATCCATCC-3' F 
pJET-R 5'-GCAGCTGAGAATATTGTAGCAGATC-3' R 
SEAPSal-F 5'-ATGTCGACTGGGAATTGGCTCCGGTG-3' F 
SEAP-R 5'-GCATCGGTCGACGGATCCTTATCGA-3' R 
pTH-F 5'-GCGTCGACGATATCGCCATT-3' F 
pTH-R 5'-CCATGATTACGCCAAGCTC-3' R 
SEAPi-F 5'-GCCAAGAAAGCAGGGAAGTC-3' F 
SEAPi-R 5'-CACATAGCCTGGACCGTTTC-3' R 
lucQ-F 5'-CAACTGCATAAGGCTATGAAGAGA-3' F 
lucQ-R 5'-ATTTGTATTCAGCCCATATCGTTT-3' R 
SEAPQ-F 5'-CCTTGACCCCGCACAGGTA-3' F 
SEAPQ-R 5'-GGCTCTGTCCAAGACATACAATGTA-3' R 
Rep-F 5'-TCCATCGTGCGTCAGATTTGCG-3' F 
polyA35SS-F 5'-AGGGTTCTTATAGGGTTTCGCTC-3' F 
CMV-R 5'-CCCTGTAACGTATGTGAGA-3' R 

















Sequence analysis was used to confirm correct sequence identity of each stage of the cloning 
process, as well as the final vectors. Sequencing was performed by Macrogen Inc., and multiple 
sequence alignment was done using CLC Main Workbench 6 bioinformatics analysis software 
(CLCbio). 
 
2.2.4. Growth and maintenance of HEK293TT cells 
 
HEK293TT cells were used for all mammalian expression experiments. Cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM), with 10% Fetal Calf Serum (FCS, v/v), 1% nonessential 
amino acids (NEAA, v/v), and 1% penicillin/streptomycin (v/v). Cells were maintained in T75 cell 
culture flasks (Corning), and incubated at 37° C, with 5% CO2, and 95% humidity. Cells were passaged 
when they reached 90% density, with a seeding density of 10% (approximately 1x105 cells/ml).  
 
Table 2.2 | PCR reactions used in this project 







OE-PCR 1 A+B pRIC3 I 1676 68 3 
  2 C+D pRIC3 II 644 68 3 
 
3 E+F pRIC3 III 234 61 1.5 
  4 G+H pRIC3 IV 323 61 1.5 
 
5* A+D I+II pR3fr-M 2295 68 3 






3075 60 1.5 
  8 pTH-F and -R pTHpCapRluc 
 
4120 51 3 
colony PCR 9 pJET-F and -R pJET1/blunt MCS 
 
2295 60 1.5 
  10 SEAPi-F and -R SEAP gene fragment 
 
795 53 2.5 
 
11 G and Rep-R pRIC3 fragment 
 
1275 61 3 




fragment in pJET  
554 51 4.5 





2235 60 2.5 


















83 54 1.5 
















2.2.5. Reporter gene expression testing in HEK293TT cells  
 
In order to verify activity of the mammalian reporter cassettes, unencapsidated, endotoxin-free 
plasmid DNA was prepared from 100ml E.coli shake cultures using the EndoFree Plasmid Maxi Kit 
(QIAGEN) following kit instructions, and used to transfect HEK293TT cells, using the FuGENE 6 
Transfection reagent (Promega). The FuGENE transfection protocol was followed; briefly, cells were 
seeded in 6-well plates at a density of 0.2x106cells/ml, and allowed to grow for 24h (50-60% 
confluency). FuGENE:DNA ratios of 3:1, 3:2 or 6:1 were tested.  3 or 6µl of FuGENE transfection 
reagent was incubated in 97µl of serum- and antibiotic-free DMEM for 5 minutes at room 
temperature.  1-2µg of plasmid DNA was added to this mixture, mixed gently and incubated for a 
further 30 minutes, before the mixture was added dropwise to cells. Cells were incubated for 72h. 
For the plasmids containing the SEAP expression cassette, cell culture medium was harvested. For 
those containing the luciferase expression cassette, media was removed, the cells were washed 
once with PBS, and an appropriate volume of Cell Culture Lysis Buffer (Promega, 20µl for 96-well 
plates, 400µl for 6-well plates) was added to the cells. Cells were rocked on an orbital shaker for 15 
minutes, and stored at -20° C overnight. 
 
To measure luciferase production in mammalian cells, the Luciferase Assay System kit (Promega) 
was used, as per kit instructions. 100µl luciferase substrate luciferin was added to 20ul of cell lysate. 
Luminescence was read on a Modulus Microplate Reader (Turner BioSystems). 
 
Western Blotting was used to confirm SEAP expression after transfection. 32µl of cell culture media 
from cells transfected with the SEAP cassette was used for SDS-PAGE, as described in Section 3.2.6. 
Blots were probed with a sheep-produced polyclonal anti-calf intestinal alkaline phosphatase (anti-
ciAP) primary antibody (Abcam, ab7330), and mouse anti-sheep alkaline phosphatase-conjugated 


















2.3.1. Introduction of restriction enzymes sites into pRIC3 to create pRIC3.2 
 
In order to ligate new mammalian cassettes into the pre-existing structure of the pRIC3 plasmid, 
restriction enzyme sites needed to be introduced at the 3’ and 5’ ends of the extant plant expression 
cassette in pRIC3. To achieve this, overlap extension PCR was used (OE-PCR, see Fig. 2.6). Proof-
reading polymerase system ACCUZYME™ (Bioline) was used for all OE-PCR steps to avoid unwanted 
mutations. Figure 2.10 shows the PCR reaction to amplify mutated fragments I-IV from pRIC3 
(reactions 1-4, Table 2.2). Fragments of the expected size (fragment I, 1676bp; fragment II, 644bp; 
fragment III, 234bp; and fragment IV, 323bp), as well as positive controls, are indicated by red boxes. 
Secondary PCR products can be seen in the + and fragment I lanes – fragment I encompasses one of 
two LIR regions found in pRIC3, and this may lead to non-stringent annealing, and amplification of 
secondary products. Mutated fragments of the correct size were excised and purified, before being 
used as a template for the next stage of the overlap extension PCR. 
 
OE-PCR product pR3fr-M (2295bp) was amplified using primer pair A and D, from fragments I and II. 
Colony PCR using pR3fr-M-specific primers (reaction 5, Table 2.2) which amplified a 2295bp DNA 





Figure 2.10 | PCR amplification of fragments for OE-PCR PCR was used to introduce SalI and XhoI restriction 
enzyme sites. Fragment I was amplified using primers  A and B, fragment II using primers C and D, fragment III 
using primers E and F, fragment IV using primers G and H. Red boxes indicate bands of the expected size. MW, 
molecular weight marker (sizes are indicated); SalI, reactions for the introduction of SalI site; XhoI, reactions for 
















fragment confirmed the successful ligation of pR3fr-M into cloning vector pJET1/blunt (Fig. 2.11A). 
Lanes 1, 2, 4, 5, 7, 8, and 11 are positive, while smaller products indicate incorrect ligation (lanes 3, 
6, 9 and 10). SalI restriction enzyme digestion of pJET-pR3fr-M recombinant clones was used to 
confirm the successful introduction of the 5’ SalI restriction enzyme site by OE-PCR (Fig 2.11B) by 
comparison to theoretical digest fragment sizes. The pJET backbone contains a SalI site at position 
168, approximately 370bp upstream of the MCS, resulting in the two digestion products seen here. 
Thus, fragments of approximately 3.4Kbp and 2Kbp, or 4.5Kbp and 1Kbp, were expected for 
presence of SalI, in forward or reverse orientation, while no mutation would result in a linearised 
vector of approximately 5.5Kbp. Colonies 1, 2 and 5 (Figure 2.11B) likely represent pR3fr-m, with the 
SalI mutation, in the forward orientation, while colony 4 represents the fragment in the reverse 
orientation, resulting in fragment sizes of approximately 4.5Kbp and 1Kbp.  
 
Similarly, OE-PCR was used to amplify pR3fr2-M (539bp) from fragments III and IV, using primer pair 
E and H (Figure 2.6), then ligated into cloning vector pGEM-T Easy (Promega) to form pGEM-pR3fr2-
m. Colony PCR with pR3fr2-M-specific primers E and H (reaction 6, Table 2.2), which amplified a 
539bp fragment, confirmed the presence of recombinant clones (Fig 2.12A). Positive clones were 
further screened for successful restoration of the XhoI restriction enzyme site by XhoI restriction 
enzyme digestion (Fig 2.12B); linearised vector of approximately 3.5Kbp indicated presence of an 









Figure 2.11 | Cloning of fragment pR3fr-M Colony PCR and Restriction enzyme digest of recombinant pJET-
pR3fr-M. (A) Colony PCR amplification of a 2295bp fragment (←) confirms successful ligation of pR3fr-M into 
pJET1/blunt vector. MW, molecular weight; 1-12, recombinant clones. (B) SalI digest of positive clones 
confirms the presence of pR3fr-M insert, and successful introduction of a new SalI site. Expected fragments 















XhoI site, while no digest occurred in those clones lacking the mutation. Several positive pJET-pR3fr-
M and pGEM-pR3fr2-M clones were selected for sequencing analysis. 
 
pR3fr-M and pR3fr2-M OE-PCR fragments were sequentially ligated into the original pRIC3 vector, 
using restriction sites located at the 5’ and 3’ ends of each fragment (BglII and EcoRV for pR3fr-M; 
XbaI and BamHI for pR3fr2-M). Figure 2.13 shows colony PCRs to screen for recombinant clones, as 
well as restriction enzyme digests to confirm that ligations were performed correctly. PCR primers G 
and Rep-R (reaction 11, Table 2.2) were designed to amplify a 1275bp fragment containing the newly 
introduced pR3fr2-M to confirm recombinant pRIC3.1 clones (pRIC3 with an introduced XhoI site at 
the 3’ end of the plant cassette, Fig. 2.13A). Lanes 1, 2, 4, 7, 8, 9, and 12, Fig. 2.13A, show positive 
clones, while religated ‘empty’ vector resulted in smaller PCR products of approximately 500bp, as 
seen in lanes 3, 5, 6, 11, 13, and 14, Fig. 2.13A. Similarly, primers A and D (reaction 5, Table 2.2) were 
used to amplify the pR3fr-M fragment ligated into pRIC3.1, to confirm the presence  
A 
Figure 2.12 | Cloning of fragment pR3fr2-M C lony PCR and restriction enzyme digest of recombinant 
pGEM-pR3fr2-M. (A) Colony PCR amplification of 539bp fragment (←) confirms successful ligation of 
pR3fr2-M into pGEM-T Easy vector. MW, molecular weight; 1-14, recombinant clones; -, negative colonies. 
(B) XhoI digest of positive clones confirms the presence of pR3fr2-M insert, and successful introduction of a 
new XhoI site. An indicated fragment (←) indicates the presence of XhoI site at the correct location. MW, 
molecular weight; 1, 3, 4, 6, 7, 9, 12-14, recombinant clones; -, undigested DNA. 
MW    1     2      3      4      5      6      7      8       9      10   11   12    13    14       -      -   
1KBp 
500bp 






























Figure 2.13 | Cloning of intermediates pRIC3.1 and pRIC3.2 Colony PCR of recombinant pRIC3.1 and pRIC3.2, 
and restriction digest of pRIC3.2. (A) Colony PCR amplification of a 1275bp fragment (←) confirms successful 
ligation of pR3fr-M into original pRIC3 vector. MW, molecular weight; 1-14, recombinant clones; (B) Colony 
PCR amplification of a 2295bp fragment (←) confirms successful ligation of pR3fr2-M into pRIC3.1 vector. MW, 
molecular weight; 1-11, recombinant clones; +, positive control pRIC3. (C) XhoI and SalI digest of pRIC3.2 
confirms the presence of SalI and XhoI sites. Digested fragments are indicated (←). MW, molecular weight 
marker; S, SalI digest; X, XhoI digest; S+X, SalI and XhoI digest; -, no digest (negative control). 


















of recombinant pRIC3.2 clones (pRIC3.1 with SalI site introduced at the 5’ end of the plant cassette, 
Fig. 2.13B). Although not clear in this image, lanes 1-5, and 11, Fig. 2.12B, were positive, indicating 
the presence of pR3fr2-M in pRIC3 to form pRIC3.2. Recircularised ‘empty’ vector would result in no 
product being amplified, as is the case for lanes 6-10. Restriction enzyme digest of pRIC3.2 with SalI 
and XhoI was used to confirm the presence of the introduced restriction sites in recombinant 
pRIC3.2 clones (Figure 2.13C), with fragments corresponding to expected sizes of 1776 and 4706bp 
(lane S+X). Digestion of pRIC3.2 with SalI and XhoI alone (lanes SalI and XhoI) indicates linearization 
of the vector by a single digestion event, while no digestion (lane -) showed coiled and supercoiled 
plasmid DNA, as expected. Several recombinant clones were picked for DNA sequencing, and were 
confirmed to possess the correct sequence and nucleotide mutations using CLC Main Workbench 6 
bioinformatics analysis software (CLCbio).  
2.3.2. Preparation of mammalian expression cassettes for cloning into pRIC3.2 
 
Two mammalian expression cassettes were utilised in this study. The cassette containing the SEAP 
gene (mSEAP) came from expression vector pYSEAP, developed by Pastrana et al. (2004). The SEAP 
cassette was successfully amplified by PCR from pYSEAP, with the introduction of a 3’ SalI site, using 
primer pair SEAPSal-F and SEAP-R (reaction 7, Table 2.2) to generate a 3075bp fragment with SalI 
sites at both 3’ and 5’ ends. This PCR product was purified and ligated into the vector pJET1/blunt, to 
form pJET-mSEAP. Colony PCR using the same primer pair amplified a 3075bp fragment to identify 
successful recombinant pJET-mSEAP clones – lanes 2, 3, 4, 6, 7, 9, and 1 (Figure 2.14). Recircularised 
‘empty’ pJET1/blunt showed no amplification products – lanes 1, 5, and 8. Lane + shows a PCR 
MW      1       2       3       4        5        6       7       8        9      10       +  
500bp 
2Kbp 
Figure 2.14 | Cloning of SEAP mammalian expression cassette Colony PCR of recombinant pJET-mSEAP clones. 
Colony PCR (A) amplification of 3075bp fragment (←) confirms successful ligation of mSEAP cassette into 
















performed using the ligation mix as a template – a secondary band in the region of 600bp is likely 
amplified from incorrectly ligated product. 
 
To form the luciferase cassette (mluc) and incorporate the pCapR enhancer element, luciferase was 
cloned from commercial vector pGL3-promoter into a modified pTH vector to form pTHpCapRluc 
(see Figure 2.5C). The mluc cassette was then amplified with incorporated 5’ SalI and 3’ XhoI sites 
from intermediate pTHpCapRluc, and ligated into pJET1/blunt. pJET1/blunt MCS primer pJET-F, and 
CMV I/E/P-specific primer CMV-R (reaction 12, Table 2.2) were used to identify recombinant pJET-
mluc clones (pJET with the full mluc cassette, Figure 2.15). These primers amplified a 554bp product 
in lane 7, which confirmed the presence of recombinant pJET-mluc clones, while all other lanes 
showed no product, indicating that the mluc cassette was not present. 
 
2.3.3. Construction of replicating vectors pRIC3-mSEAP, pRIC3-mSEAP+, and pRIC3-mluc+ 
 
The final vectors were created by ligating the mammalian cassettes into the pRIC3.2 intermediate via 
SalI and/or XhoI digestion (see Figures 2.7, 2.8, and 2.9). PCR primers SEAPi-F and SEAPi-R (reaction 
10, Table 2.2) were designed to amplify a 795bp fragment of the SEAP gene were used to screen for 
recombinant pRIC3-mSEAP (Fig. 2.16A) and pRIC3-mSEAP+ (Fig. 2.16B) clones by colony PCR. A 
795bp band indicated recombinant clones (lanes 1, 3-9 and 11-15, Fig 2.16A; lanes 14 and 17, Fig. 
2.16B), while religated ‘empty’ pRIC3.2 clones showed no amplification product. Primers lucQ-F and 
lucQ-R (reaction 15, Table 2.2) were designed to amplify a 153bp fragment of the luc gene. Colony 
PCR using these primers resulted in recombinant pRIC3-mluc+ clones, as indicated by a 153bp band  





Figure 2.15 | Cloning of luciferase mammalian expression cassette Colony PCR of recombinant pJET-mluc 
clones. Colony PCR amplification of 554bp fragment (←) confirms successful ligation of mluc cassette into 
















1    2      3      4     5      6    7     8     9    10   11  12   13   14   15  16  17  18   19   20 
500bp 
1Kbp 
MW    1     2      3       4       5      6       7      8      9     10    11    12    13    14    15    16 
1Kbp 
Figure 2.16 | Construction of replicating vectors Colony PCR and restriction enzyme digest of pRIC3-mSEAP, 
pRIC3-mSEAP+ and pRIC3-mluc+.  Colony PCR (A) amplification of a 795bp fragment (←) confirms recombinant 
pRIC3-mSEAP clones.MW, molecular weight marker; 1-16, recombinant clones. Colony PCR (B) amplification of 
a 795bp fragment (←) confirms recombinant pRIC3-mSEAP+ clones. 1-16, recombinant clones. Colony PCR (C) 
amplification of 153bp fragment (←) confirms recombinant pRIC3-mluc+ clones. MW, molecular weight 
marker; 1-10, recombinant clones; -, negative control (no colony); +, positive control (pTHpCapRluc). SalI and 
XhoI restriction enzyme digest (D) of final vectors confirms correct plasmid size and construction. MW, 
molecular weight marker; S, SalI digest; X, XhoI digest; S+X, SalI and XhoI digest; -, no digest (negative control). 
 
MW     1         2         3         4         5         6         7         8        9        10         -        +   
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In lanes 2, 3, 5, and 7-10 (Fig 2.16C). Religated ‘empty’ pRIC3.2 vector showed no amplification 
products. Restriction digest of the final vectors using SalI and XhoI (Fig 2.16D) was used to confirm 
that the mammalian cassettes had been ligated as expected. pRIC3-mSEAP digestion showed that 
SalI cut the vector once (the SalI site at the 3’ end of the mSEAP cassette was destroyed by ligation 
with XhoI on the pRIC3.2 vector), while XhoI cut the vector twice – there are two XhoI sites in close 
proximity within the SEAP cassette. Digestion with both SalI and XhoI resulted in fragments of 241bp 
(Fig. 2.16, indicated by a red box; could not be visualised), 1855bp and 5885bp. pRIC3-mSEAP+ 
digestion showed that SalI cut the vector twice, at the 3’ and 5’ ends of the mSEAP cassette, as 
expected. XhoI cut the vector in three places – twice in the interior of the SEAP gene, as for pRIC3-
mSEAP, and once at the re-introduced site 5’ of the plant cassette, which was not used for pRIC3-
mSEAP+ cloning. SalI and XhoI digestion revealed five bands of 241bp (indicated by a red box), 
983bp, 1776bp, 1855bp (not visible as separate fragments), and 4906bp, as expected.  pRIC3mluc+ 
was cut once by each enzyme, SalI at the 5’ end of the mluc cassette, and XhoI at the 3’ end. Double 
digestion resulted in fragments of 4906bp (mluc cassette) and 5864bp (pRIC3 backbone), again 
visible only as a single band.  
2.3.4. Sequencing of vectors 
 
Sequencing of key intermediates and all three final vectors (not shown) was performed, and 
analysed using CLC Main Workbench 6 bioinformatics analysis software (CLCbio). Sequence analysis 
confirmed the presence and orientation of all expected elements of the final vectors – see Figures 
2.7, 2.8, and 2.9 for complete plasmid maps. The mluc cassette was introduced in the same 
orientation as the plant  cassette, while the mSEAP cassette was introduced in the reverse 
orientation in both pRIC3-mSEAP and pRIC3-mSEAP+. 
2.3.5. Testing of mammalian pseudogenome reporter activity in HEK293TT cells 
 
In order to confirm that the mammalian cassettes introduced into the pRIC3 plasmid would be 
functional as reporter pseudogenomes, the plasmids were transfected into mammalian cells to test 
for reporter protein expression. Endotoxin-free plasmid DNA was prepared, and cells were 
transfected using FuGENE 6 Transfection Reagent. Cells were transfected with various FuGENE:DNA 
ratios to determine the best ratio for future transfection work. For pRIC3-mSEAP and pRIC3-mSEAP+, 
cell culture media was harvested 72 hours post-transfection, while for pRIC3-mluc+, cells were lysed 
and harvested 72h post-transfection. A western blot probed with a rabbit-produced anti-SEAP 
antibody showed SEAP expression at the expected 65kDa size, at various FuGENE:DNA ratios (Figure 



















culture media. There was no notable difference in expression between constructs or at different 
ratios, except for 3:2 for pRIC3-mSEAP+, which showed no SEAP expression. Luciferase expression 
was assayed by adding luciferin substrate to cell lysate, and recording relative luminescence on a 
luminometer (Figure 2.17B). Transfection at all three ratios resulted in luciferase expression at 
2.42x103-2.55x104 RLU, compared to a baseline value (negative control) of 4.39 RLU. A FuGENE:DNA 
ratio of 6:1 was marginally better than the other two ratios. These experiments were independently 
performed at least three times, and images in Fig. 2.17 are representative. These results suggest that 
these vectors will be useful for the production of reporter pseudogenomes in plants. 
 
  





Figure 2.17 | Reporter gene expression in HEK293TT cells (A) Western blots of cell culture media shows SEAP 
expression (→) 72h post-transfection with pRIC3-mSEAP or pRIC3-mSEAP+ plasmid DNA at various 
FuGENE:DNA ratios. MW, molecular weight marker, sizes are indicated; -, negative control (FuGENE only); +, 
positive (commercially available calf intestinal alkaline phosphatase, Sigma). (B) Comparison of luc expression 
in various FuGENE:DNA transfection ratios 72h post-transfection with pRIC3-mluc+ in relative light units (RLU). 








































In order to produce mammalian cassettes for PsV production in plants, autonomously replicating 
vector pRIC3 was modified to incorporate two different mammalian reporter gene cassettes, 
luciferase and SEAP. The luciferase vector contained both plant and mammalian expression 
cassettes, while SEAP-expressing vectors were produced both with and without a plant expression 
cassette, in order to vary the size of pseudogenomes to be made in plant host cells. Three resulting 
vectors were created, namely pRIC3-mSEAP, pRIC3-mSEAP+ and pRIC3-mluc+ (replicon sizes of 
4.8Kbp, 6.4Kbp, and 7.4Kbp, respectively). The sequence identity of these vectors was confirmed, 
and they were used to transfect mammalian cells in order to test whether the reporter genes under 
the influence of mammalian promoters were expressed. All three vectors showed reporter gene 
expression 72h post-transfection in HEK293TTcells, demonstrating that the mammalian reporter 
cassettes encoded by these vectors are functional in mammalian cells, and will thus be useful for the 
production of effective reporter pseudogenomes in plants.  
2.4.1. Development of novel replicating constructs 
 
Replicating plant expression vectors have been developed by several researchers, usually using 
viruses of the family Geminiviridae. They have traditionally been developed for use as plant 
expression vectors, for the transient production of recombinant proteins at large scale (Hefferon, 
2012). These replicon systems promise high recombinant protein expression levels, rapid transient 
expression, and improved versatility over traditional plant expression vectors and transgenic 
systems (Gleba et al., 2007). Several approaches to replicating plant expression vectors have been 
attempted – these include constitutive 2- or 3-vector systems (a notable example would be 
magnifection, as espoused by ICON Genetics) (Gleba et al., 2007; Hefferon and Fan, 2004; Mor et al., 
2003), an alcohol-inducible 2-vector system (Zhang and Mason, 2006), and single vector systems 
(Huang et al., 2009; Palmer et al., 1999; Regnard et al., 2010). Additionally, several replicons have 
recently been incorporated into a single vector, with no apparent deleterious effect on protein 
expression and yield (Huang et al., 2010). These replicating vectors all rely on the rolling circle 
replication (RCR) mechanism to amplify the gene copy number of a transgene by several orders of 
magnitude, with the aim of improving on transgene expression by non-replicating vectors.  
 
 Interestingly, there are also several recent reports on the use of virus-derived replicating 
mammalian expression vectors. These have been used for a range of purposes, including gene 















tool to study replication processes in mammalian cells (Takeda et al., 2005). Of particular interest is 
the work by Faurez et al. (2010), who constructed PCV-2-derived vectors which replicate via the RCR 
model, and investigated the rate of rolling circle replication. PCV-2 is an ssDNA circovirus with many 
similarities to geminiviruses, including a compact, ambisense genome, rep gene, and rolling circle 
replication mechanism. (Mankertz et al., 2004). Further, rep sequence analysis for PCV identified 
nucleotide and amino acid sequence motifs similar to those found in geminivirus rep, which in both 
virus families are required for rolling circle replication (Mankertz et al., 1997). 
 
Genetic elements from a wide variety of sources were used to create the sophisticated replicating 
vectors used in this project (See Figures 2.7, 2.8, and 2.9). The ‘backbone’ of each of these vectors is 
comprised of an origin of replication (ori) for replication in both E. coli (ColE1 ori) and A. tumefaciens 
(RK2 ori), as well as an ampicillin resistance gene (bla), features common to many other plant 
expression vectors, such as pTRAc (Maclean et al., 2007) and pEAQ (Sainsbury et al., 2009). Another 
aspect common to all agroinfiltration is the RB and LB, which are short (25bp) near-identical 
nucleotide sequences that flank the region of DNA transferred into plant cells during agroinfiltration 
(T-DNA). In pRIC and pRIC3, two copies of the BeYDV LIR are located immediately inside the borders 
of the T-DNA. Along with the products of the BeYDV rep gene, Rep and RepA, these allow the 
formation of the initiator complex for the rolling circle replication mechanism (Khan, 2005). The 
remaining elements found in pRIC3 make up the plant expression cassette – cauliflower mosaic virus 
35S promoter and polyA signal were chosen as they have been shown to drive strong constitutive 
transgene expression in plants (Maclean et al., 2007). An MCS was incorporated to allow for easy 
cloning of various transgenes. 
 
While replicating vectors, including pRIC3, have proven useful for transient, high-level recombinant 
protein expression, the replicating ability of pRIC3 was not used for that purpose in this study. 
Rather, the extremely efficient rolling circle replication mechanism was exploited for the production 
of PsV pseudogenome DNA at high copy number, and subsequent encapsidation by coexpressed 
structural proteins for the production of particles. This is a more efficient and elegant solution than 
delivery of a non-replicating pseudogenome vector for intracellular assembly, or in vitro 
disassembly-reassembly of VLPs in the presence of pseudogenome DNA. To our knowledge, this is 
the first demonstration of this approach for PsV production. 
 
To facilitate the insertion of mammalian cassettes into the pRIC3 vector, restriction enzyme digest 















vector construction by previous investigators in our lab (Ogle, 2008; Regnard et al., 2010) utilised a 
SalI site located at the 5’ end of the CamV35Spromoter element, and an XhoI site at the 3’ end of 
pA35SS polyadenylation signal (Figure 2.2). While the sites were destroyed by ligation with 
compatible restriction enzyme sites, they were able to be restored by the introduction of a single 
nucleotide mutation at each site. Site-directed mutagenesis thus provided a relatively 
straightforward way to introduce the mammalian cassettes into pRIC3. 
 
Overlap extension PCR was used for the site-directed mutagenesis required in both cases. This 
involved several stages of PCR amplification of different fragments in order to incorporate the 
required nucleotide changes. Following OE-PCR, mutated fragments pR3fr-M and pR3fr2-M were 
each cloned into a vector for sequencing (Figure 2.6). pR3fr-M was cloned into pJET1/blunt, while 
pR3fr2-M was cloned into pGEM-T Easy. Different cloning vectors were used due to difficulties in 
cloning pR3fr2-M into pGEM-T Easy. Cloning PCR products into pJET1/blunt proved an easier method 
due to the vector being designed for blunt-end cloning. Subsequently, fragments pR3fr-M and 
pR3fr2-M were ligated into pRIC3 via unique restriction sites located at the 3’ and 5’ ends of these 
fragments, namely BglI and EcoRV for pR3fr-M, and XbaI and BamHI for pR3fr2-M. This new 
construct, designated pRIC3.2, was now ready for the introduction of the two new mammalian 
cassettes. 
 
The choice of mammalian cassette elements was based on past availability and success. Both SEAP 
and luc are widely used as robust and reliable reporter genes in mammalian systems (Jiang et al., 
2008). The mSEAP cassette was taken entirely from pYSEAP, a plasmid developed by Pastrana et al. 
(2004), and chosen due to its wide-spread use for PBNA. The use of SEAP for reporter assays is a 
relatively recent development, in comparison to other reporter gene assays developed, such as 
luciferase assays (Berger et al., 1988). It was identified as a sensitive and robust assay in comparison 
to other common reporter assays, and is considered the superior reporter gene for pseudovirion-
based neutralisation assays. It offers a significant advantage over other reporter genes for this 
purpose, in that it is a secreted protein, and as such there is no need for cell lysis. Luciferase, on the 
other hand, has been in use for many years as a reporter gene. Luc expression is read as 
luminescence, and it has become widely used due to its rapidity, sensitivity and ease of use (Contag 
and Bachmann, 2002). Further, it provides an advantage over SEAP, in that it is less than half the cost 
per reaction when comparing the two kits used in this project (Luciferase Assay System, Promega; 
and Great EscAPe Chemoluminescence Kit, Clontech Laboratories, Inc.). Two new luciferase assays 















(Shao and Bock, 2008), and a newly developed Nanoluc, from Promega (Hall et al., 2012). Both these 
have demonstrated to be far more sensitive than traditional luciferase assays, and may be better 
choices for this reporter system. The non-gene elements of the mluc cassette, namely a 
cytomegalovirus intron/enhancer/promoter element, PCV pCapR enhancer element, and a SV40 
polyadenylation signal, have been demonstrated to induce high expression of an HIV polyprotein in 
HEK293 cells (Tanzer et al., 2011). The pCapR enhancer element incorporated into the mluc cassette 
is comprised of two regions, namely the Pcap core, and the conserved late element (CLE, shown in 
Fig. 2.3). These regions, identified using the Transcompel database, comprised a slightly larger 
portion of the genome than that described as the minimal Pcap region (Mankertz and Hillenbrand, 
2002), and incorporated previously unidentified putative transcription factor binding sites. This 
172bp fragment contains consensus DNA binding sites for c/EBPb, a transcription factor involved in 
control of cell cycle progression; GATA-1, a constitutive Zn finger transcription factor; and CREB, a 
cAMP response element binding protein, in the Pcap core, which form a putative composite 
transcription factor binding site. The 172 bp fragment also contains the smaller CLE, with putative 
binding sites for transcription factors SP1 and AP3 in. The addition of this region to pTHgrttnC in 
reverse orientation (pTHPcapRgrttnC) resulted in a stable plasmid and significantly improved 
expression of GrttnC protein in mammalian cells when compared to pTHgrttnC (Tanzer et al., 2011). 
As such, its inclusion in the mluc cassette is likely to aid in the expression of luciferase in mammalian 
cells. 
 
Construction of vectors pRIC3-mSEAP, pRIC3-mSEAP+, and pRIC3-mluc+ was successful, as confirmed 
by restriction enzyme mapping and sequence analysis. The SEAP cassette was introduced into 
pRIC3.2 which either had been linearised by digestion at the introduced SalI site 5’ of the plant 
expression cassette, or had the plant cassette removed via digestion at the introduced 5’ SalI and 3’ 
XhoI sites. This resulted in the vectors pRIC3mSEAP+ and pRIC3mSEAP, respectively. Notably, 
orientation of the SEAP cassette was not controlled for, as the SEAP cassette was flanked by SalI 
sites on the 3’ and 5’ ends. As such, the final vectors contain the SEAP cassette in the reverse 
orientation to the original plant cassette. This did not have any effect on the functionality of the 
SEAP reporter cassette, as demonstrated by successful SEAP expression in mammalian cells. The 
mluc cassette was introduced at the 3’ end of the plant cassette to form pRIC3mluc+. The motivation 
for creation of this vector was two-fold. The first reason was to evaluate more than one reporter 
gene, due to the relative expense of PBNA using SEAP. The second reason was to create a larger 
replicon than those produced by pRIC3mSEAP and pRIC3mSEAP+ (4.8 and 6.6 Kbp, respectively). The 















has been suggested that DNA packaging efficiency of HPV PsVs produced in mammalian or insect 
cells is related to the size of the pseudogenome packaged – several researchers have demonstrated 
that DNA is packaged more efficiently when the plasmid is close to 8Kbp, and that plasmids smaller 
than 5Kbp or larger than 8Kbp are not packaged (Buck et al., 2005b; Holmgren et al., 2005; Touze 
and Coursaget, 1998). 
2.4.2. Testing of reporter gene activity in mammalian cells 
 
The results obtained here demonstrate that both of these reporter genes, in all three created 
vectors, are expressed at appreciable levels in mammalian cells. There is also no evidence to suggest 
that the presence of a plant expression cassette had any effect whatsoever on mammalian reporter 
gene expression, at least in the case of SEAP. We can conclude that both SEAP and luc assays are 
sensitive enough for the purposes of the PBNA. Further, there is little difference in terms of speed 
and ease of use. Luciferase appears to be a more suitable reporter gene for our purposes, due to its 
lower cost per assay reaction.  
 
The plant gene present in the larger plasmids pRIC3mSEAP+ and pRIC3mluc+ is not relevant to the 
project, other than to increase the size of the final replicon. However, it may be useful for further 
investigations to incorporate a plant reporter gene such as EGFP in this cassette, to allow for easy 
confirmation of replication in plants (as demonstrated by Regnard et al. 2010 with the pRIC 
predecessor plasmid). There may be some value in incorporating a gene to improve replication of 
the replicon; however, it has been suggested that the replication efficiency is close to saturation 
point for the plant replicative machinery, and as such this approach may have little effect (Zhang and 
Mason, 2006). Another interesting approach would be to test the inclusion of a chaperone gene. 
Several studies have shown that HPV virion assembly is mediated by intracellular chaperones, and 
this inclusion of a chaperone gene in these vectors may assist in PsV assembly in planta (Bird et al., 




In this study, three novel replicating vectors were successfully created from the previously 
developed pRIC3. Two of these carry a SEAP mammalian reporter cassette, while the third carries a 
luciferase mammalian reporter cassette. Correct construction and orientation of these plasmids was 
confirmed by restriction enzyme and sequencing analysis. The inclusion of these mammalian 















vectors will be used to agroinfiltrate plants, to allow for autonomous replication to take place, and 
















Chapter 3: Expression of HPV L1/L2 VLPs and PsVs in plants and PsV 
testing in mammalian cells 
3.1. Introduction 
 
Cervical cancer caused by high-risk HPV is the second most prevalent cancer in women in developing 
countries; Africa in particular has been identified as a high risk region for the disease (Ferlay et al., 
2010). Recently developed L1 VLP vaccines, Cervarix® and Gardasil™, protect against HPV-16 and -
18, or HPV-6, -11, -16 and -18 infection, respectively.  Both currently available vaccines elicit a strong 
and protracted neutralising antibody response, and have been shown to have sustained efficacy up 
to 5 years post-administration (Harper et al., 2006; Villa et al., 2006). While these vaccines are 
showing great promise in reducing the burden of disease, development and production of VLP 
vaccines remains prohibitively expensive, particularly in developing countries. 
 
A key element of any HPV vaccine development initiative is the pseudovirion-based neutralisation 
assay (PBNA). Induction of neutralising antibodies is currently the best estimate of vaccine candidate 
efficacy for second generation HPV vaccine testing. Until recently, the identification of serum 
neutralising antibodies relied on the use of enzyme-linked immunosorbent assay (ELISA) or 
neutralisation assays using whole virus (Dessy et al., 2008).  However, improvements in HPV  
pseudovirion production efficiency in the last decade have allowed the development of the 
pseudovirion-based neutralisation assay (PBNA). Developed by John Schiller’s group at the Center 
for Cancer Research at the NIH, this assay uses mammalian cells for intracellular production of PsVs 
expressing a SEAP reporter gene (Buck et al., 2005a), and has since become the gold standard for 
testing neutralisation of candidate HPV vaccines, allowing rapid and un-biased screening of 
neutralising antibodies and epitopes (Stanley et al., 2008). While this production method has been 
shown to be extremely effective for production of PsVs, SEAP assay kits are particularly expensive in 
comparison to other commonly used reporter assays such as luciferase or GFP. There is a need, 
therefore, to develop alternative PsV production methods to allow for affordable candidate vaccine 
development and testing. 
3.1.1. Development of HPV neutralisation assays  
 
The production of neutralising IgG antibodies in response to vaccination has long been understood 
to be a key aspect of protective immunity (Robbins et al., 1995). It has been suggested that it may be 















provided that the concentration, isotype and secondary biological activity of these antibodies could 
be accurately measured (Robbins et al., 1995). Neutralisation assays were developed as a method of 
accurately quantifying the neutralising capabilities of immune sera, usually in response to a live viral 
or vaccine candidate challenge, as well as identify neutralising epitopes (Ochsenbauer and Kappes, 
2009; Yeager et al., 2000).  
 
The first demonstration of in vitro neutralisation of papillomavirus was by Dvoretzky et al. (1980), 
who demonstrated neutralisation with rabbit-produced BPV-1 antisera to confirm the role of BPV-1 
in focus formation in mouse cell lines. Early efforts to establish a robust, sensitive in vitro 
neutralisation assay were hampered by difficulties in production of infectious virus. Production of 
infectious virions in vitro was first achieved by grafting HPV-11-infected material into athymic mice: 
grafts were left to develop into condylomatous cysts over a period of 3-5 months, before being 
harvested and purified for HPV virions (Kreider et al., 1987). This method was utilised to produce 
virions for use in the first de facto neutralisation assay. Neutralising monoclonal antibodies were 
identified and isolated from HPV-11 or BPV-1 antisera. These antibodies were then used to 
demonstrate neutralisation of intact virions by ELISA, as well as identifying several neutralising 
conformational epitopes (Christensen et al., 1990). The same group used this method to successfully 
identify neutralising HPV antibodies in human sera for the first time, and further demonstrated that 
ELISA was a good indicator of the presence of neutralising antibodies in human sera (Christensen et 
al., 1992). Another approach coupled the neutralisation of HPV-11 infection with RT-PCR detection 
of HPV mRNA transcripts to create a semi-quantitative neutralisation assay (Smith et al., 1995). 
While these approaches were nominally successful in identification of neutralising antibodies, 
detection remained limited at best, and the procedures used were time-consuming and expensive. 
 
A major step forward in neutralisation assay technology came with the advent of PsV production, 
which abrogated the need for the expensive and time-consuming xenograft production method. 
Roden et al. (1996) used hamster BPHE-1 cells to generate BPV-1 or HPV-16 PsVs. These were used 
to demonstrate focus formation in C127 cells, using the technique demonstrated by Dvoretzky et al. 
(1980). These researchers further showed that neutralising antibodies in HPV-16 antisera prevented 
focus formation, demonstrating a quantitative neutralisation assay of a high-risk HPV type using PsVs 
for the first time (Roden et al., 1996). In this report, the authors noted that the focus transformation 
assay required 2-3 weeks, and that inclusion of a marker or reporter gene would greatly improve the 
speed of the assay. This was first attempted by chemically linking a β-lactamase (BLAM) reporter 















mammalian cell lines. Early attempts demonstrated neutralisation, but resulted in <1% infection of 
cells with these PsVs (Muller et al., 1995). Yeager et al. (2000) and Bousarghin et al. (2002) 
demonstrated this approach more successfully, using a BLAM or luc reporter plasmids and an 
alternative method of attaching the plasmid to VLPs. More importantly, several groups generated 
PsVs with encapsidated reporter genes, and demonstrated their use for neutralisation assays (Buck 
et al., 2005a; Fleury et al., 2008a; Kawana et al., 1998; Rossi et al., 2000; Stauffer et al., 1998; Touze 
and Coursaget, 1998; Unckell et al., 1997). While early attempts were inefficient due to poor PsV 
production levels, this was improved upon by intracellular generation of high yields of L1/L2 PsVs 
and incorporation of a SEAP reporter plasmid (Buck et al., 2004). These PsVs were used with a 
commercially available SEAP detection kit to demonstrate a pseudovirion-based neutralisation assay 
that was at least as sensitive as, and potentially more type-specific than, the standard ELISA-based 
neutralisation assay (Pastrana et al., 2004).  
 
While the system developed by Pastrana et al. (2004) is considered the current ‘best practice’ 
neutralisation assay, there remains room for improvement. In particular, the costs of PsV production 
could be greatly decreased by the use of a less expensive production system (Brondyk, 2009). 
Recombinant protein expression in plants has been demonstrated to have a significantly lower cost 
of production when compared to production in mammalian cells (Tiwari et al., 2009). Thus, plant 
expression may provide an attractive alternative for the production of PsVs for use in the PBNA. 
3.1.2. Protein expression systems in plants 
 
Expression of recombinant proteins in plants has developed over the last twenty years from a 
curiosity in the late 1980’s to a medically and industrially relevant production system today. Early 
efforts relied on transformation of plants to produce stable transgenic lines. This was achieved 
through biolistic delivery or, more recently, agroinfiltration (Daniell et al., 2009).  While transgenic 
protein production remains a useful and viable system, advances in transient expression methods 
and technology have positioned transient expression as the preferred method for industrial-scale 
production in plants (Rybicki, 2010). Two key factors that have played a central role in this transition 
are viral, or virus-derived, expression vectors, and the development of agroinfiltration technology.  
 
Agroinfiltration was originally developed to as an alternative to biolistic bombardment for the stable 
transformation of plants (Kapila et al., 1997). This process relies on the DNA transfer capability of A. 
tumefaciens to introduce foreign DNA to plant cells. A. tumefaciens can be used to transfer a 















a bacterial suspension of the transformed bacterium. The T-DNA is transported to the plant nucleus, 
and this allows for transformation of the plant through integration of the T-DNA into the plant 
genome (Zupan et al., 2000). Importantly, however, a transgene incorporated into the T-DNA is also 
transiently expressed from episomal DNA, resulting in systemic expression of a recombinant protein 
without the need for stable transformation (Kapila et al., 1997).  
 
Viral vectors were the first transient expression method developed for plants. Early efforts simply 
inserted a recombinant gene or epitope into the genome of viruses such as Tobacco mosaic virus 
(TMV), Cowpea mosaic virus (CPMV) or (Potato virus X (PVX), either fused to the viral coat protein or 
separately, under control of a duplicated constitutive viral promoter (Durrani et al., 1998; Gleba et 
al., 2007; Turpen et al., 1995). While this application produced immunogenic protein, expression 
levels were lower than those found in transgenic plants. Other problems with these ‘first-generation’ 
viral vectors included a tendency to revert to the natural virus, constraints on insert size, difficulty of 
administration, and an inability to form VLPs (Kohl et al., 2006; Rybicki, 2010; Varsani et al., 2006).  
These limitations prompted further work to develop ‘second generation’, or deconstructed, viral 
vectors. This approach used only the desirable viral elements, in particular the replicative machinery, 
to manufacture synthetic vectors capable of inducing transgene expression in plants (see Figure 3.1). 
While these vectors are usually not infectious on their own, when coupled with agroinfiltration 
















technology they can result in systemic transient expression of protein at levels comparable to or 
greater than that of transgenic plants (Tiwari et al., 2009). This approach has the advantages of short 
time frames (3-7 days) when compared to stable transformation (6-9 months), significant expression 
levels, and rapid and easy scale-up and purification. This makes agroinfiltration-mediated transient 
expression via viral vectors an ideal approach for the production of medically relevant proteins and 
particles in plants. Of particular interest is the use of transient expression for the production of VLPs 
and PsVs in plants, as there is potential for a reduction in cost when compared to traditional systems 
(Santi et al., 2006). 
3.1.2. HPV VLP production in plants  
 
Papillomavirus L1 VLPs have been produced by several groups in plants. Most have used transgenic 
plants (Biemelt et al., 2003; Varsani et al., 2003; Warzecha et al., 2003) with resulting low yields. 
Early attempts at transient expression of L1 also yielded low levels of expression, as well as an 
apparent inability to form VLPs (Varsani et al., 2006). However, agroinfiltration of a vector encoding 
a human codon-optimised L1 protein provided a much higher protein yield, and demonstrated that 
transient expression of HPV-16 VLPs at high levels is a feasible approach for the production of 
immunogenic HPV candidate vaccines (Maclean et al., 2007). 
 
The non-replicating vector used to produce L1 at such high expression levels – pTRAc – was 
developed at the Fraunhofer Institute for Molecular Biology and Applied Biology. This vector utilises 
 
Figure 3.2 | Agrobacterium expression vector pTRAc P35SS, CaMV 35S promoter with duplicated 
transcriptional enhancer; CHS, chalcone synthase 5’ untranslated region; pA35S, CaMV 35S polyadenylation 
signal; SAR, scaffold attachment region of the tobacco Rb7 gene; LB and RB, the left and right borders for T-
DNA integration; ColE1ori, origin of replication for E. coli; RK2ori, origin of replication for Agrobacterium; 
















a CaMV 35S promoter with duplicated transcriptional enhancer, chalcone synthase 5’-untranslated 
region, and CaMV 35S polyadenylation signal for foreign gene expression (see Figure 3.2).This vector 
has also been used to express the minor capsid protein L2 in plants (Pereira, 2008). However, 
coexpression of L1 and L2 has not previously been conclusively demonstrated to form VLPs in planta. 
3.1.3. The potential for PsV production in plants 
 
Encapsidation (or covalent attachment) of DNA by HPV VLPs to form PsVs has been demonstrated in 
yeast, insect, bacterial and mammalian cell systems (Buck et al., 2005a; Roden et al., 1996; Rossi et 
al., 2000; Unckell et al., 1997). Buck et al. (2005) demonstrated that intracellular encapsidation of 
the pseudogenome is more efficient than in vitro disassembly-reassembly methods for the 
production of HPV PsVs, probably due to cellular factors that assist in correct assembly of the virions  
(Buck et al., 2008; Fleury et al., 2008a; Peng et al., 2011) . Currently, HPV pseudovirions have not 
been successfully expressed in plant expression systems. As discussed above, transient expression in 
plants offers several significant advantages for this application: protein expression in plants has been 
shown to be safe, cheaper than other expression systems, and potentially extremely rapid (Ma et al., 
2005; Schillberg et al., 2005). A further significant advantage is that there is no need for downstream 
processing of proteins (e.g. glycosylation), as for bacterial recombinant protein expression systems 
(Giorgi et al, 2010). While it has been noted that N-glycosylation may differ in plants (specifically, 
plants cannot synthesise β-1,4-galactose and sialic acid), this problem can be overcome by recent 
advances in transgenic tobacco to provide ‘humanised’ glycosylation machinery (Bakker et al., 2006; 
Gleba et al., 2007). Further, it has been suggested that glycosylated L1 is not an important part of 
the assembled virion (Zhou et al., 1993b). 
 
In this study, we aimed to evaluate the feasibility of expressing HPV L1/L2 pseudovirions with an 
encapsidated mammalian reporter cassette in planta. To achieve this, pTRAc plasmids expressing L1 
and L2 proteins were co-infiltrated into plants with novel autonomously replicating plasmids, 
developed in this study, to potentially create HPV L1/L2 PsVs. Further, we aimed to purify these 
















3.2. Materials and Methods 
3.2.1. Plant expression vectors  
 
To express PsVs in N. benthamiana plants, several plant expression vectors were utilised. The 
construction of the replicating vectors used for replicon formation, namely pRIC3-mSEAP, pRIC3-
mSEAP+, and pRIC3-mluc+, was covered in Chapter 2. Further to these, the plant expression vector 
pTRAc (gifted by Prof. Dr. Rainer Fischer; Fraunhofer Institute for Molecular Biology and Applied 
Ecology, Germany) expressing HPV-16 L1 or L2 human codon-optimised genes (pTRAc-hL1 and 
pTRAc-hL2, respectively) were used for production of L1 and L2 capsid proteins. This vector, shown 
in Fig. 3.2, targets L1 and L2 expression to the cytoplasm, and pTRAc-hL1 has demonstrated high 
transient expression levels for L1 in planta (Maclean et al., 2007). 
3.2.2. Transformation of Agrobacterium tumefaciens 
 
Plasmids were isolated from E. coli using a QIAGEN Plasmid Miniprep Kit. These were then 
introduced into Agrobacterium tumefaciens strain GV3101::pMP90RK via electroporation, as 
described by Maclean et al. (2007). A. tumefaciens cells were made electrocompetent by the 
method described by Shen and Forde (1989). 200ng of plasmid DNA was added to a chilled 
electroporation cuvette (Molecular BioProducts, Inc.), along with 100µl of electrocompetent cells. 
After 5 minutes of incubation on ice, cells were electroporated using a Bio-Rad GenePulser™ under 
the following conditions: 1.8kV, 25µF, 200Ω. 900µl of antibiotic-free Luria broth was added to the 
electroporated cells, which were incubated for 2 hours at 27°C. Recombinant clones were screened 
by antibiotic selection with rifampicin (50µg/ml), carbenicillin (50µg/ml), and kanamycin (30 µg/ml). 
Plates were incubated at 27°C for 48 hours to allow for colony formation, and screened for positive 
clones by colony PCR.  
3.2.3. Agroinfiltration of N. benthamiana 
 
Agroinfiltration of N. benthamiana plants was performed as described by Maclean et al. (2007). 
Nicotiana benthamiana plants were grown from seed in a controlled plant growth room. The plants 
were grown at 22°C, with 16 hours of light per day for 6 weeks. Plants were agroinfiltrated by 
syringe or by vacuum with a bacterial suspension of recombinant A. tumefaciens at an optical 
density (OD) of 0.25, 0.5, 0.75 or 1. Briefly, a syringe was used to force A.tumefaciens bacterial 
suspension into the abaxial air spaces in several leaves per plant. The plants were allowed to grow as 















whole plants were submerged in 500ml of bacterial suspension, and placed in a vacuum chamber. A 
vacuum of -90 kilopascal (kPa) was maintained for 5 seconds, then rapidly released (10-15kPa.sec-1). 
Plants were grown as normal, and harvested at 4 dpi.  
3.2.4. Quantitative PCR 
 
qPCR analysis was performed to determine whether replication of the replicon was occurring in  
plants. A single 0.5cm leaf disc was incubated at 95°C for 10 minutes with 100µl Extraction Buffer 
from the Extract’n’Amp Plant PCR Kit (Sigma Aldrich). This was diluted with 100µl Dilution buffer, 
and stored at -20°C until needed. qPCR was performed using the 2x SybrGREEN ReadyMix from the 
same kit. Primers lucQ-F and lucQ-R (reaction 16, Table 2.2; see also Table 2.1) were used to amplify 
a 153bp fragment of the luciferase gene, and primers SEAPQ-F and SEAPQ-R (reaction 17, Table 2.2) 
were used to amplify an 83bp fragment of the SEAP gene. All primers were used at a final 
concentration of 0.4µM. qPCR cycling was performed on a Corbett RotorGene 6000 (Corbett), using 
cycling parameters as follows: 95°C for 2 minutes; 40 cycles of 95°C for 5 seconds, variable annealing 
temperature for 5 seconds, and 72°C for 5 seconds; and melt curve analysis from 72-95°C for 5 
seconds per degree. qPCR was performed with three technical repeats per sample, with a sample 
population size of three (N=3). Data was analysed using RotorGene Q Series 2.0.2 software (Corbett). 
Ct values were converted to replicon copy number in Microsoft Excel 2010 (Microsoft) and values 
were normalised to total DNA concentration for each sample. 
3.2.5. Inverse PCR 
 
A variation of Inverse PCR, as described by Regnard et al. (2010), was utilised to confirm 
recircularisation of the replicon (Figure 3.3). Primers were designed to amplify a DNA fragment 
(approximately 2.1Kbp) encompassing the site of recircularisation for each replicon (See table 2.1). 
Table 2.2, reactions 13 and 14, show the PCR reactions used. Reaction conditions are described in 

















3.2.6. SDS-PAGE and western blotting 
 
SDS-PAGE was performed to analyse HPV-16 hL1 and hL2 protein production in plants. Protein was 
extracted from plants agroinfiltrated with A. tumefaciens GV3101::pMP90RK pTRAc-hL1 and/or 
pTRAc-hL2. Briefly, three 0.5cm leaf discs were harvested at 1, 3, 5, and 7dpi, frozen in liquid N2, and 
ground in a microcentrifuge tube using a plastic pestle. 100µl of 0.5M NaCl PBS with 1x Complete 
EDTA-free protease inhibitor cocktail (Roche) (hL1) or 8M urea in H2O (hL2) was added to the ground 
leaf material and mixed thoroughly. Samples were centrifuged at 13000rpm for 5 minutes, and the 
supernatant was reserved. This centrifugation step was repeated, and the supernatant was stored at 
-20°C. For SDS-PAGE analysis, 8µl of 5X loading dye containing β-mercaptoethanol was added to 32µl 
of soluble protein, and samples were incubated at 95°C for 7 minutes. These were then loaded on 
10% SDS-polyacrylamide gels using the Mini-PROTEAN® Tetra SDS-PAGE system (Bio-Rad), and 
electrophoresed at 130V for approximately 120 minutes. These gels, and nitrocellulose membranes, 
were equilibrated for 10 minutes in transfer buffer before being transferred to a nitrocellulose 












NO PRODUCT PRODUCT 
Figure  3.3 |Principle of Inverse PCR Diagram illustrating the principle of inverse PCR. Primers (→) designed to 



















Cell. Membranes were incubated with blocking buffer for 60 minutes, then probed for L1 overnight, 
using commercially available CamVir-1 primary monoclonal antibody (Abcam, ab69) diluted 1 in 
10000 in blocking buffer. Membranes were washed for 4x 10 minutes in blocking buffer, probed with 
goat anti-mouse AP-conjugated secondary antibody (Sigma, A3562) diluted 1 in 5000 in blocking 
buffer for two hours, washed 4x 10 minutes in blocking buffer without skim milk powder, and 
visualised using BCIP/NBT Phosphatase substrate (KPL). For L2, a similar protocol was employed. 
Primary antibody was rabbit-produced anti-L2 primary polyclonal serum produced in our laboratory 
and used at 1 in 5000 dilution, and secondary antibody was goat anti-rabbit AP-conjugated antibody 
(Sigma, A3687).  
3.2.7. Extraction and purification of particles 
 
To produce particles, plants were vacuum-infiltrated with A. tumefaciens GMV3101::pMP90RK 
containing pTRAc-hL1, pTRAc-hL2 and either pRIC3luc, pRIC3mSEAP or pRIC3iSEAP. Protein and DNA 
were harvested at 4 dpi, as described in Section 3.2.6. Western blotting, as described in Section 
3.2.6., was used to confirm the presence of L1 and L2 protein, and inverse PCR, as described in 
Section 3.2.5., was used to confirm that replicational release had taken place. Whole plants were 
harvested 4 dpi. Particles were purified following a variation of the protocol described by Varsani et 
al. (2003), with some modifications. Whole leaves were weighed, and ground with liquid nitrogen in 
a pestle and mortar, or macerated thoroughly at room temperature. Cold 0.5M NaCl-PBS was added 
to the leaf material at a ratio of 1:2 (w:v), and samples were homogenised in an T25 Ultra-Turrax 
high shear mixer (IICA®) at 13000rpm for 10’ on ice. Homogenate was kept on ice for a further 2 
hours before being centrifuged at 8000xg for 20’ at 4° C in a Beckman Coulter Avanti J25i centrifuge 
with a Beckman JA-14 rotor. Supernatant was filtered through 4 layers of Miracloth (Calbiochem), 
and layered onto a 7ml, 40% sucrose cushion (w/v). The samples were centrifuged at 100000g for 3h 
at 4° C in a Optima™ L-100 XP centrifuge (Beckman Coulter) with a Beckman Coulter SW32Ti rotor. 
The supernatant and sucrose cushion were removed, the pellet was resuspended in 1ml 0.4g/ml CsCl 
in PBS, and clarified on an Eppendorf 5424 tabletop centrifuge at 13000rpm for 10’. The supernatant 
was diluted in 5ml of 0.4g/ml CsCl in PBS, and subjected to centrifugation at 100000xg for 24h in an 
L-100 XP ultracentrifuge with a Beckman SW55Ti rotor at 10° C.  
3.2.8. Identification of VLPs and PsVs in CsCl gradient 
 
After centrifugation, the CsCl gradient was fractionated manually or using a Foxy Jr. fractionator 















refractive index at 25° C, and International Critical Tables (Kellogg, 1927) were used to convert 
refractive index to buoyant density.  
 
A dot blot was performed to confirm the presence of L1 in the CsCl fractions. Briefly, 1 µl of each 
fraction was dropped onto a nitrocellulose membrane. The membrane was blocked for 30’ in 
blocking buffer, then probed for L1 as described in Section 3.2.6. Membranes were scanned and 
analysed using GeneTools densitometry software (SynGene), and relative spot intensity was 
normalised to L1 presence in crude plant extract. L1-positive fractions were pooled and dialysed 
overnight against 0.5M NaCl in PBS to remove CsCl. 
 
In order to confirm the presence of the DNA replicon in the PsVs, inverse PCR was performed as 
previously (Section 3.2.5). Proteinase K was added to the fractions, which were incubated at 55° C 
for 3h to allow full digestion of the PsV protein shell, before undergoing inactivation at 95° C for 10’. 
PCR reactions 13 and 14 (Table 2.2) were used to amplify an approximately 2.1Kbp DNA fragment in 
these samples.  
3.2.9. Electron microscopy 
 
To confirm the presence of VLPs and PsVs, transmission electron microscopy (TEM) was used. 
Copper grids were rendered hydrophilic by glow-discharge using a Model 900 SmartSet Cold Stage 
Controller (Electron Microscopy Sciences) at 25mA for 30 seconds. Grids were incubated for 1-30’ 
with VLP or PsV samples, washed three times with dH2O, and particles were stained with 2% uranyl 
acetate (w/v). Grids were view d on a Tecnai F20 transmission electron microscope (FEI) or a 
LEO912 transmission electron microscope (Zeiss) at 14500X, 19000X or 50000X magnification. 10 
fields of view were captured at 50000X magnification for all samples, and three fields of view were 
captured at 19000X magnification for L1/L2 VLP samples, and 14500X for PsV samples. PsV 
proportions were estimated by counting 3 fields of view for each PsV type, and calculating that as a 
percentage of the total number of PsVs per field. 
3.2.10. Pseudovirion neutralisation assay 
 
To determine whether plant-produced PsVs were useful for PBNA, mammalian cells were 
pseudoinfected with plant-produced PsVs. HEK293TT cells were trypsinised and resuspended in 
neutralisation media (standard growth media, using DMEM lacking in phenol red) at a density of 
0.3x106cells/ml, and plated at 100µl/well in a 96-well plate. Cells were grown at 37°C for 3-4h. 60µl 















described in Section 2.2.5. Luc activity was assayed as described previously (Section 2.2.5.). SEAP 
activity was assayed using the Great EscAPe SEAP Chemiluminescence Kit (Clontech Laboratories, 
Inc.), at 0.6 volumes of those described in kit instructions. Briefly, 50µl of cell culture media was 
harvested at 72h post-transfection. 15µl were added to 45µl dilution buffer, and incubated at 65°C 
for 30 minutes. Samples were placed on ice for 5 minutes, before 60µl of SEAP Substrate Solution 
was added, and samples were incubated at room temperature for 30-60 minutes. Luminescence was 
detected on a Modulus Microplate Reader (Turner BioSystems) for 10 seconds. All samples were 
assayed in triplicate, and standard deviation was calculated for all samples  
 
Neutralisation of PsVs was assayed using a known HPV-16 neutralising antibody, following the 
protocol described by Buck et al. (2005a). HEK293TT cells were prepared as described in Section 
4.2.3. 60µl of PsVs were incubated with 15µl neutralising antibody HPV-16.V5 (developed by 
Christensen et al. (1996a)) at a dilution of 1 in 4000 (for a final dilution 1 in 20000) on ice for 60 
minutes. 75µl of PsVs were added dropwise to cells in triplicate, and cells were incubated for 72 
hours. Luciferase and SEAP activity were assayed as previously described (luciferase, see section 
2.2.5.; SEAP, see section 4.2.3.). Standard deviation was calculated for all samples. 
3.3. Results 
3.3.1. Replicating vectors undergo replicational release in plants 
 
Three novel vectors, pRIC3-mSEAP, pRIC3-mSEAP+ and pRIC3-mluc+ were designed and tested in N. 
benthamiana. All three vectors were cloned into A. tumefaciens GV3101::pMP90RK, and plants were 
infiltrated at an OD600 of 0.5. DNA was harvested from plants at 3dpi, and tested for replicational 
release by PCR. Primers were designed to amplify a 2.1Kbp fragment of the replicon, incorporating 
the LIR (see Figures 2.7C, 2.8C and 2.9C) – reaction 13 for pRIC3mluc+, and reaction 14 for pRIC3-
mSEAP and pRIC3-mSEAP+ (Table 2.2). A PCR amplification product would only be produced in the 
MW       mSEAP     mSEAP+      plant  
2K
B 
MW         mluc+       plant 
2KB 
A B 
Figure 3.4 | Novel constructs demonstrate replication in plants PCR amplification of (A) pRIC3-mSEAP and 
pRIC3-mSEAP+ and (B) pRIC3-mluc+ replicons shows replicational release of T-DNA. MW, molecular weight 
marker; mSEAP, pRIC3-mSEAP; mSEAP+, pRIC3-mSEAP+, mluc+, pRIC3-mluc+, plant, uninfiltrated plant DNA 















presence of recircularised replicon. PCR amplification (Figure 3.4) of an approximately 2.1Kbp 
product confirmed that the replicon was formed in plants individually infiltrated with pRIC3-mSEAP 
(Fig. 3.4A), pRIC3-mSEAP+ (Figure 3.4A), and pRIC3-mluc+ (Fig. 3.4B). This confirms that these 
vectors form a recircularised replicon in plant cells, and are suitable vectors for pseudogenome 
production. 
3.3.2. Optimisation of protein and DNA expression in plants 
 
Expression of hL1 and hL2 was optimised by a 1-7dpi time trial. Plants were agroinfiltrated with a 
range of bacterial suspension OD600 values (0.25-1.0). Protein was harvested at 1, 3, 5, and 7dpi, and 
separated by SDS-PAGE. hL1 and hL2 expression was analysed by western blotting using anti-L1 
CamVir-1, and an anti-L2 polyclonal antibody raised in rabbits (Figure 3.5), respectively. Expression 
of recombinant protein was detected at all OD600 values tested, from 3dpi, for both hL1 and hL2, at 
MW       d1           d3          d5          d3          d5           d3            d5            + 
OD                       0.25                             0.5                          1.0 
70 
100 
MW    d1           d3        d5       d7         d1         d3        d5          d7         +          d1       d3          d5          d7         +       MW 





Figure 3.5 | Optimisation of L1 and L2 expression Timetrial of (A) hL1 and (B) hL2expression levels at various 
infiltration ODs, at 1-7 and 1-5 dpi, respectively. Protein is indicated (→) at 55kDa (hL1) and approximately 
65kDa (hL2). MW, molecular weight marker, with sizes indicated in kDa; +, crude plant-produced hL1 (A) and 















the expected size. While L2 is an approximately 50kDa protein, it has been widely observed to 
migrate at approximately 80kDa (Muller et al., 1995). The highest expression detected for hL1 was at 
OD600 0.25, from 3-7dpi (Fig. 3.5A). The highest expression of hL2 was also seen in those plants 
infiltrated at OD600 0.25, at 3dpi (Fig. 3.5B). Agroinfiltration parameters of OD600 0.25 at 4dpi were 
chosen for optimal hL1 and hL2 expression in further experiments. 
 
The pRIC3 vector backbone has been previously demonstrated to form replicons that replicate to 
high copy number within the plant cell, relative to non-replicating vector pTRAc (Regnard et al., 
2010). Plants were infiltrated individually with each replicating vector at OD 0.5, and DNA was 
harvested at 1, 3, 5 and 7dpi. qPCR was used to determine the increase in replicon copy number 
from 1 to 7dpi with each of the replicating vectors. Reactions 15 and 16 (Table 2.2) were used for 
pRIC3mluc+, and pRIC3-mSEAP and pRIC3-mSEAP+, respectively. Analysis showed a 100-1000-fold 
increase in gene copy number for all three vectors at from 1 to 3dpi, with maintenance at similar 
copy number up to 7dpi (Figure 3.6). pRIC3-mSEAP (Fig. 3.6A), pRIC3-mSEAP+ (Fig. 3.6B) and pRIC3-
Figure 3.6 | qPCR timetrial of replicating vectors qPCR analysis of DNA extracted from plants infiltrated with 
(A) pRIC3-mSEAP, (B) pRIC3-mSEAP+, and (C) pRIC3-mluc+, 1-7dpi. Copy number is calculated from total DNA 










































































































mluc+ (Fig3.6C) all show very similar increases in copy number. This is consistent with previous 
observations for pRIC and pRIC3 (Ogle, 2008; Regnard et al., 2010).  
 
3.3.2. Production of PsVs in plants 
 
 To produce HPV PsVs, N. benthamiana plants were co-infiltrated with pTRAc-hL1 and pTRAc-hL2, 
along with one of pRIC3-mSEAP, pRIC3-mSEAP+, or pRIC3-mluc+. Based on data shown in Section 
3.3.2, agroinfiltration with pTRAc vectors was at an OD600 of 0.25, while replicating vectors were 
agroinfiltrated at OD600 of 0.5, and particles were harvested at 4dpi. pTRAc-hL1 and pTRAc-hL2 were 
also co-infiltrated without a replicating vector, with the intention of producing HPV L1/L2 VLPs. This 
was performed by vacuum infiltration for the production of large volumes of biomass. DNA and 
crude protein were extracted at 4dpi, in order to confirm the presence of all components necessary 
for PsV formation by PCR and western blotting (Figure 3.7). PCR amplification of a 2.1Kbp fragment 
confirmed that replicon formation was occurring for all three replicating constructs at 4dpi (Figure 
3.7, panels A and B). Lanes demarcated ‘PsV’ indicate replicon formation in plants co-infiltrated with 
pTRAc-hL1 and -hL2, while those marked ‘+’ are from plants infiltrated with replicating vector alone, 
and serve as a positive control. Western blotting analysis with CamVir-1 (hL1) and a rabbit polyclonal 
antibody (hL2) confirmed expression of both L1 (Fig. 3.7C) and L2 (Fig. 3.7D) at 4dpi, in plants 
infiltrated with L1 and L2 alone (‘VLP’), or L1 and L2 coinfiltrated with a replicating vector (‘mSEAP’, 
‘mSEAP+’ and ‘mluc+’). This was independently confirmed in at least three separate co-infiltration 
experiments. Notably, the intensity of the band corresponding to L2 (Fig. 3.7D) showed marked 
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Figure 3.7 | Expression of PsV structural elements PCR was used to confirm presence of (A) pRIC3-
mSEAP, pRIC3-mSEAP+, and (B) pRIC3-mluc+ replicons 3dpi, in plants co-infiltrated with pTRAc-hL1, 
pTRAc-hL2 and pRIC3-mSEAP, -mSEAP+ or -mluc+, respectively. A band at approximately 2.1Kbp (→) 
indicates replicational release. MW, molecular weight marker, sizes shown on left; PsV, crude plant 
extract; +, DNA only (positive control); -, plant DNA (negative control). Western blotting for L1 (C) and L2  
(D) confirm presence of both structural HPV proteins 4dpi in crude extract from plants co-infiltrated with 
pTRAc-hL1, pTRAc-hL2 and pRIC3-mSEAP, -mSEAP+ or -mluc+. VLP, pTRAc-hL1 and –hL2 only; mSEAP, 
pRIC3-mSEAP PsV, mSEAP+, pRIC3-mSEAP+ PsV; mluc+. pRIC3-mluc+ PsV; +, crude plant-produced hL1 (C) 
or bacterially produced L2 (D); MW, molecular weight marker, sizes indicated in kDa. 

























3.3.3. Purification and identification of plant-produced PsVs 
 
Having confirmed the presence of all necessary elements comprising PsVs in infiltrated plants (L1 
protein, L2 protein, as well as mSEAP, mSEAP+ and mluc+ replicons), VLPs and PsVs were isolated 
from crude plant extract using variations of the method described by Varsani et al. (2003). Briefly, 
homogenised PsV-containing plant material was subjected to ultracentrifugation on a 40% sucrose 
cushion. The resulting pellet was resuspended in 0.4g/ml CsCl in PBS, and subjected to isopycnic 
ultracentrifugation to separate particles on the basis of buoyant density.  
 
After centrifugation, samples were fractionated and analysed for the presence of L1 by dot blotting, 
using anti-L1 CamVir-1, as it was thought that this would indicate the presence of VLPs and PsVs as a 
result of its association with L1, a vital component of these particles. Densitometry analysis of L1 
signal on the dot blots indicated the presence of putative HPV VLPs or PsVs, and compared to the 
buoyant density of each fraction of the gradient, calculated as a function of refractive index (Figure 
3.8). Previous work has reported that HPV L1/L2 VLPs with encapsidated DNA (PsVs) have a buoyant 
density of 1.32-1.34 g/ml, while VLPs (without DNA) have a buoyant density of 1.26-1.28g/ml (Rossi 
et al., 2000; Touze and Coursaget, 1998). L1 was seen to be present in all fractions, with a distinct 
peak in signal corresponding to a buoyant density of 1.33g/ml, suggesting that these particles 
contain encapsidated DNA (Figure 3.8). Interestingly, L1/L2 VLPs demonstrated an L1 peak at a 
buoyant density of 1.30-1.33g/ml, which corresponds to a ‘heavy’ particle (Figure 3.8A). This 
suggests that these particles had possibly encapsidated nucleic acid with similar efficiency to those 
co-infiltrated with replicating vectors. A secondary peak was seen at a density of 1.25g/ml in L1/L2 
VLPs (Fig. 3.8A) and at a density of 1.27g/ml in particles purified from plants infiltrated with pRIC3-
mSEAP (Figure 3.8B). This suggests that in these two samples, small quantities of particles were 
formed without encapsidated DNA. These results are each representative of at least three separate 
purification procedures. Fractions 8-11 were pooled and dialysed against high-salt PBS to obtain 
purified PsVs, and fractions 17-18 were pooled and dialysed as a non-PsV control. These were used 



















































































































































L1 Presence in mluc+ PsV CsCl Gradient 
1             2                 3                    4                  5 
6                7                 8*                9*                
10* 
11*             12              13                14                 15 
 16              17               18                19                 + 
1             2                  3                   4                 5 
6             7                  8*                 9*              10* 
11*        12                13                14                15 
16          17               18                  19               + 
1              2                3                4                5 
6               7                8*             9*               10* 
11*           12              13              14              15 
16              17             18             19              + 
1                 2                 3                   4                 5 
6               7                 8*               9*             10* 
11*          12               13                14              15 





Figure 3.8 | Caesium chloride gradient ultracentrifugation of VLPs and PsVs Densitometry analysis of L1 
dot blots shows distribution  of L1 after Caesium chloride  ultracentrifugation and fractionation. Dot Blots 
(left panels) of CsCl fractions 1-19 were probed with CamVir-1 anti-L1 antibody. * on dot blots, and grey 
panel on graphs, indicate fractions pooled for dialysis; +, crude plant extract (positive control). Density of 
CsCl fractions (♦) was compared to relative intensity (□, arbitrary units) of L1 (right panels) to estimate 
















 Figure 3.9 shows several key stages in the purification process, separated on and SDS-PAGE gel. 
Coomassie staining reveals the removal of the majority of protein contaminants from the purified 
samples (Fig. 3.9A and B). A protein band is present at approximately 55kDa in purified samples in 
both Figure 3.9A and 3.9B, which is probably purified L1. L2, which migrates at approximately  
70kDa, is not visible in the Coomassie-stained gels. This is expected, as L2 is present in HPV VLPs and 
PsVs in much smaller quantities than L1 (a maximum ratio of L1:L2 is estimated at 5:1). Western 
blotting analysis with CamVir-1 shows a clear increase in concentration and purity of L1 in all 
samples (3.9C and D).  
pRIC3-mSEAP         pRIC3-mSEAP+ 
   C       CsCl    dial.     C     CsCl    dial.    MW    + 
70 
55 
   C       CsCl    dial.     C     CsCl    dial.     MW     + 
VLP                   pRIC3-mluc+ 
70 
55 
pRIC3-mSEAP          pRIC3-mSEAP+ 
 C        CsCl      dial.     C       CsCl      dial.     MW    + 
70 
55 
        VLP        pRIC3-mluc+ 







Figure 3.9 Purification of PsVs Coomassie staining (A, B) and western blot for L1 (C, D) of various stages of 
purification of PsVs, separated by SDS-PAGE. Western blots were probed for L1 using the commercial anti-L1 
antibody CamVir-1. MW, molecular weight marker, sizes shown on right; C, crude plant extract; CsCl, pooled 





































In order to further confirm the presence of L1/L2 VLPs and PsVs, dialysed samples were examined by 
transmission electron microscopy (Figure 3.10). All samples showed abundant particles, of sizes 
ranging from 30-120nm. 54% of mSEAP-PsVs (Fig. 3.10A and E) were 40-70nm in diameter, while 
47% of mSEAP+-PsVs (Fig. 3.10B and F) and 50% of mluc+-PsVs (Fig. 3.9C and G) 73% of L1/L2 VLPs 
(Fig. 3.10D and H) were of a similar size. Infectious HPV virions are usually between 50 and 60nm in 
Figure 3.10 | Electron micrographs of purified PsVs (A) and (E) pRIC3-mSEAP , (B) and (F) pRIC3-mSEAP+, (C) and 
(G) pRIC3-mluc+ PsVs (previous page) and (D) and (H) L1/L2 VLPs were purified by CsCl gradient 
ultracentrifugation. Purified PsVs size varied from 30-120nm in diameter. White arrows indicate small (30-40nm) 
particles, Red arrows indicate standard-sized HPV PsV particles (50-60nm), and black arrows indicate large (100-
120nm) particles. (I) Crude plant extract serves as negative control. Scale bars are indicated (left panel, 0.5µm; 

















diameter. These particles showed a similar morphology to other examples of plant-produced HPV 
L1-only particles (Maclean et al., 2007; Warzecha et al., 2003). 
 
To confirm that replicon DNA was encapsidated to form PsVs, pooled L1-containing fractions were 
digested with proteinase K to release the encapsidated pseudogenome, followed by PCR with 
replicon-specific primers (as described in Section 3.2.5.) to confirm the presence of replicon DNA 
(Figure 3.11). PCR amplification confirmed that mSEAP, mSEAP+ (Fig. 3.11A) and mluc+ (Fig. 3.11B) 
PsVs contained the expected DNA replicon. No replicon DNA was amplified in samples not treated 
with proteinase K, indicating that the DNA was encapsidated, and not found outside of the virion 
shell. Fractions 17 and 18 from each sample were pooled and dialysed. PCR amplification of these 
fractions, before or after proteinase K digestion, as well as amplification of proteinase K-treated 
L1/L2 VLPs, yielded no amplification products.  
MW                                                             DNA                                        DNA        V          P 
PrK                    -             +             -            +                        -           +           -           +  
PsV                   +             +             -            -                        +          +            -           -  
2Kbp 
pRIC3-mSEAP pRIC3-mSEAP+ 
Figure 3.11 | Presence of DNA in purified PsVs PCR amplification of (A) pRIC3-mSEAP, pRIC3-mSEAP+, 
and (B) pRIC3-mluc+ replicon (2.1Kbp, →) indicates presence of DNA in purified PsV particles after 
digestion with proteinase K (PrK). MW, molecular weight marker; PrK +/-, PrK digestion; PsV +, pooled L1-
containing fractions, PsV -, non-L1 containing fraction (fraction 18); DNA, replicon DNA extract (positive 
control), V,  PrK-digested purified L1/L2 VLPs (negative control); P, plant DNA (negative control).   
MW                                                                    DNA         P 
PrK                   +              -               +            - 




















As a preliminary measure of quantity of PsVs in each sample, DNA concentration of proteinase K-
treated samples was read using a NanoDrop 1000 spectrophotometer (Thermo Scientific). Table 3.1. 
shows NanoDrop readings for all three PsV types. As a broad first estimate at particle concentration 
for each type, DNA concentration was used to calculate the maximum number of pseudogenomes 
present per microliter, using the formula 
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where ng is nanograms of DNA in 1µl, bp is pseudogenome size in base pairs, and NA is Avogadro’s 
constant. Results can be seen in Table 3.1. Concentration of molecules for all three PsV types was in 
the billions of particles per milliliter. This data assumes that all DNA present was pseudogenome 
DNA, and that each PsV packaged exactly one copy of the pseudogenome. Taken together, these 
results indicate the successful production in planta of PsVs containing a reporter gene for the first 
time.  
 
Table 3.1 | Estimated DNA and particle concentration of purified PsVs 
 mSEAP mSEAP+ mluc+ 
DNA (ng/µl) 8.56 14.33 14.95 








3.3.4. Pseudovirion-based neutralisation assay using plant-produced PsVs 
 
In order to demonstrate that plant produced HPV-16 PsVs are an effective biological tool for use in 
the PBNA, PsVs were tested for reporter expression in mammalian cells, as well as for neutralisation 
with a commonly used HPV-16 neutralising antibody, HPV16.V5. HEK293TT cells were grown in 96 
well plates, and pseudoinfected with 60µl of purified, undiluted PsVs in 0.5M NaCl-PBS, with or 
without prior incubation with HPV16.V5 monoclonal antibodies diluted 1:20000 in neutralisation 
media. Successful infection of mammalian cells with PsVs, as well as neutralisation of PsVs, was 
demonstrated by luc or SEAP reporter gene expression in these cells. Figure 3.12 shows reporter 
gene expression for cells 72h post-infection with mSEAP (3.12A), mSEAP+ (3.12B) and mluc+ (3.12C) 
PsVs, with or without the presence of neutralising antibodies (PsV, or PsV+NAb, respectively). The 
negative control (-ve) for each experiment – mammalian cells with 60µl of neutralisation media 















plasmid DNA is used for the positive control. Pseudoinfection with mSEAP PsVs elicited a clear 
positive SEAP response (Fig. 3.12A), although not as strong as that in cells transfected with plasmid 
DNA by lipofection. Incubation with neutralising antibody partially neutralised infection, as 
demonstrated by a decrease in SEAP signal. Pseudoinfection with mSEAP+ PsVs did not show a 
strong SEAP signal above the baseline level provided by the negative control (Fig. 3.12B). As such, 
neutralisation of mSEAP+ PsVs was not observed. Pseudoinfection with mluc+ PsVs elicited a weak 
luciferase signal, although clearly above that of the negative control. Incubation with HPV16.V5 NAb 
completely neutralised luciferase expression, resulting in expression identical to the negative 
control.  
  






































































Figure 3.12 | Reporter gene expression in PsV-pseudoinfected mammalian cells (A) SEAP expression 72 hours 
post pRIC3-mSEAP transfection (Plasmid) or mSEAP-PsV pseudoinfection (PsV) in relative light units (RLU), 
expressed in logarithmic scale (log10). (B) SEAP expression for pRIC3-mSEAP+, as previously. (C) luc expression 
for pRIC3-mluc+, as previously. –ve, negative control (media only). All experiments performed in triplicate. 

















In this study, novel autonomously replicating vectors were used in conjunction with previously 
developed, non-replicating vectors to produce HPV-16 PsVs in planta. Preliminary expression trials 
established optimal conditions and timeframes for production of each individual element required 
for assembly of HPV PsVs. The structural elements required for PsV production are hL1 and hL2, 
produced by non-replicating plant expression vectors pTRAc-hL1 and pTRAc-hL2, respectively;  and 
one of three replicons derived from pRIC3-mSEAP, pRIC3-mSEAP+ or pRIC3-mluc+. Putative PsV 
particles, as well as L1/L2 VLPs, were harvested from plants and purified by successive gradient 
ultracentrifugation steps. Gradient fractions containing L1 were pooled and dialysed against high-
salt (0.5M) NaCl PBS, to obtain purified PsVs. These were confirmed by electron microscopy to be 
conformationally similar to VLPs and PsVs produced in other systems, and by PCR to contain the 
corresponding encapsidated replicon DNA. Purified PsVs were used to demonstrate their use in a 
neutralisation assay. Two of the three PsVs created, namely mSEAP and mluc+ PsVs demonstrated 
successful pseudoinfection and neutralisation with a common HPV16 neutralising antibody, while 
mSEAP+ PsVs showed no reporter gene expression after pseudoinfection of mammalian cells. This is 
the first known report of the production and purification of HPV PsVs, as well as L1/L2 VLPs in 
planta, as well as the first demonstration of the PBNA using plant-produced PsVs.  
3.4.1. Replicational release in plants 
 
The three novel vectors discussed in Chapter 2 were tested for their ability to replicate 
autonomously in plants. PCR analysis confirmed that the appropriate replicons were formed as 
expected. To elucidate whether the autonomously replicating vectors were, in fact, producing high 
copy numbers of the replicons in planta, qPCR analysis was employed. qPCR analysis of DNA samples 
harvested up to 7dpi showed that replicon copy number for all plasmids was amplified between 100- 
and 1000-fold between 1 and 3dpi, and that this high copy number was maintained up to 7dpi. This 
is similar to the results obtained by Regnard et al. (2010), who showed a near-identical increase in 
the pRIC vectors used to generate replicons encoding the HIV p24 gene or EGFP. Replicating vectors 
developed by other groups have demonstrated similar increases in replicon copy number (Huang et 
al., 2009; Zhang and Mason, 2006). Our result demonstrates that the use of these replicating vectors 
for the generation of high quantities of double-stranded replicon DNA in plants is a feasible strategy 
















3.4.2. Production of PsVs in planta 
 
The production of HPV-16 PsVs in plants was successful for each of the three replicating vectors 
constructed. This work relied on the findings of several earlier papers, in particular that of Maclean 
et al. (2007). That study demonstrated that humanised L1 was expressed at high levels using the 
pTRAc vector, and spontaneously assembled into VLPs in planta. This, along with unpublished results 
for pTRAc-hL2 from the same group, demonstrated the feasibility of these vectors for HPV particle 
production in plants. 
 
It has been widely demonstrated that both HPV L1 and L2 are required for efficient packaging of 
DNA into the HPV virion, in both natural virions and PsVs (Ma et al., 2011; Okun et al., 2001; Stauffer 
et al., 1998). Further, it was recently established that the presence of L2 in the PsV capsid increases 
DNA packaging efficiency 10-fold (Holmgren et al., 2005). In this study, both L1 and L2 were co-
expressed to allow for maximum potential DNA encapsidation. No investigations into differential 
packaging in the presence and absence of L2 were performed; however, little or no L1 signal was 
visible in fractions 14-16 (buoyant density 1.26-1.28g/ml - corresponding to the density of VLPs with 
no encapsidated DNA). This lack of ‘light’ particles suggests that packaging of DNA by HPV particles 
in plants is very efficient indeed, resulting in few or no particles without encapsidated DNA. This is in 
contrast to other PsV production methods, all of which show a peak corresponding to ‘light’ 
particles, or VLPs. This is in particular true for the VLP disassembly-reassembly method (as 
demonstrated by Touze and Coursaget (1998)), which usually has a packaging efficiency well below 
50% (Touze and Coursaget, 1998; Unckell et al., 1997).  
 
This efficient packaging is a distinct advantage for the plant production approach, although this must 
be tempered with the observation that not all DNA packaged is necessarily pseudogenome DNA. 
This is clearly demonstrated by the L1/L2 VLPs produced here, which were seen to be mostly ‘heavy’ 
particles, indicating encapsidated DNA. As these were produced in the absence of a replicating 
vector, DNA packaged was either the pTRAc plasmids used to produce VLPs, or miscellaneous plant 
DNA. Both pTRAc-hL1 and pTRAc-hL2 (7.7Kbp and 7.5Kbp, respectively) fall below the cut-off mark of 
7.9-8Kbp for pseudogenomes that can be packaged effectively into HPV L1/L2 PsVs (Buck et al., 
2005b; Touze and Coursaget, 1998). It is possible that these plasmids, or miscellaneous DNA, were 
packaged into assembling HPV particles instead of the intended replicon DNA – it has been 
suggested that VLPs produced in mammalian cells encapsidate miscellaneous cellular DNA (Roden et 
al., 1996). In any event, the extremely efficient replication observed in the three replicating vectors 















et al., 2010), suggest that the vast majority of plasmids present in the plant during PsV assembly 
would be the reporter pseudogenomes. The potential for pTRAc plasmids to be packaged may not 
hold any relevance to the outcome of this study. Future work to elucidate all DNA species 
encapsidated into plant-produced PsVs is important for a full understanding of the PsV assembly 
process in planta, as well as for their use in neutralising assays. 
 
Structural analyses of L1 and L2 suggest that DNA associates in a non-specific manner, based on the 
overall pH and charge of internal structural motifs (Fay et al., 2004; Garcea and Gissmann, 2004; Li et 
al., 1997; Pereira et al., 2009). Presumably, this allows for in vitro PsV assembly, demonstrated by 
several investigators, in the absence of mammalian cellular factors (Oh et al., 2004; Shi et al., 2001; 
Touze and Coursaget, 1998). In mammalian cells, there is evidence to suggest that chaperones 
(particularly karyopherins) play a role in the assembly and DNA packaging of natural HPV virions, and 
it seems likely that these are responsible for efficient intracellular PsV production (Bird et al., 2008; 
Chromy et al., 2006). Chaperones, in particular Heat shock protein 70 (Hsp70) and karyopherins, 
have been shown to play a role in the assembly of diverse viruses, including plant viruses (Kunik et 
al., 1999; Sullivan and Pipas, 2001). Interestingly, the ER-associated chaperone Binding Protein (BiP) 
has been demonstrated to take part in folding and assembly of recombinant antibodies in transgenic 
plants (Nuttall et al., 2002). These data suggest that the molecular machinery required for 
papillomavirus assembly and DNA encapsidation is conserved across all eukaryote systems, and is 
responsible for the efficient PsV assembly observed here. 
3.4.3. Purification of plant-produced PsVs 
 
Purification of PsVs was performed using a protocol developed for extracting HPV VLPs from 
harvested plant material (Varsani et al., 2003). This protocol has been used successfully to extract 
VLPs of several different HPV types from plants (Maclean et al., 2007; Matic et al., 2012). This 
method proved to be successful, too, for the purification of PsVs. One concern was the use of liquid 
N2 for preliminary grinding of plant material. While this step was not, in itself, a problem, cycles of 
freezing and thawing, as well as freezing plant material for long-term storage at -70°C, resulted in 
degradation of PsV particles (data not shown). As such, the protocol was modified slightly to replace 
grinding of frozen leaf material with finely chopping the leaf material in high-salt PBS before 
proceeding directly to the homogenisation step. This alteration noticeably decreased degradation of 
PsVs – PCR amplification of the replicon before purification of PsVs showed much more amplification 
















Electron micrographs clearly demonstrate the successful assembly and isolation of HPV L1/L2 VLPs 
and PsVs in plants. The PsVs produced demonstrated an unusual variability in size, when compared 
to other VLP and PsV production methods (Buck et al., 2004; Maclean et al., 2007; Touze and 
Coursaget, 1998). The broad size range, from 30nm to 120nm in diameter, may be due to pooling of 
fractions corresponding to CsCl density of 1.30-1.33g/ml. HPV L1/L2 PsVs should be found at a 
density of 1.32-1.34g/ml, and as such, some PsVs smaller and larger than the expected 50-60nm size 
range may have been pooled, resulting in the variability shown. Other researchers have seen similar 
results in transgenic plants, and suggest that the smaller-sized particles may be assembly 
intermediates (Biemelt et al., 2003). It is also possible that the differential sizes seen here are due to 
an assembly process that differs substantially to that of HPV virions in mammalian cells. 
 
Previous work has included a maturation step, to allow PsV capsid formation in vitro (Buck et al., 
2004). This approach was tested by the inclusion of a 2-hour incubation at 4C after plant tissue 
homogenisation. EM data revealed no differences in quantity or quality of PsVs produced with or 
without this step, and as such it was omitted from future purifications. 
 
Previous reports on the production of HPV PsVs has used benzonase treatment coupled with PCR to 
demonstrate that DNA is encapsidated within the virion shell, and not merely associated with the 
virion (Rossi et al., 2000; Unckell et al., 1997). Benzonase also decreases the viscosity of the lysate, 
and frees capsid proteins associated with cellular DNA. PsVs produced in this study were not 
degraded by the 95°C PCR denaturation step, as demonstrated by no amplification of 
pseudogenome DNA in PsV samples not digested with proteinase K. As such the protein shell needed 
to be digested prior to PCR pseudogenome amplification in order to demonstrate the presence of 
pseudogenome DNA. The significance of this is twofold. Firstly, benzonase treatment was not 
required to demonstrate encapsidation of DNA, and was subsequently not used. Second, and 
possibly more importantly, this demonstrates that these PsVs are remarkably stable, even under 
mildly denaturing conditions. This is an important observation. VLPs are generally relatively 
unstable, and need to be treated with some care to avoid collapsing the particle (Mach et al., 2006). 
While PsVs are generally more stable, most that have been produced in other systems are not as 
stable as these plant-produced PsVs have been demonstrated to be. Accordingly, this suggests an 
important advantage over traditional PsV production systems.  
 
The data presented here is the first clear evidence for successful production and purification of 















VLPs was useful, in that it allowed a comparison of VLPs and PsVs produced in plants. Electron 
micrographs clearly show regular particles of 40-70nm in diameter. The low number of VLPs shown 
relative to the numbers of PsVs is a result of less starting material – VLPs were purified from 
approximately 25% (by fresh leaf weight) of the crude plant material used for PsV production. 
Western blots seen in Figure 3.6 (panels C and D) clearly show the presence of both L1 and L2 in 
plants co-infiltrated with pTRAc-L1 and pTRAc-L2. Levels of L2 varied noticeably between different 
co-infiltration experiments, including co-infiltrations for the production of PsVs. This is not 
unsurprising, in that the ratio of L1:L2 has been shown to vary between 5:1 and 30:1 in HPV virions 
and L1/L2 VLPs. This first evidence of L1/L2 VLP production in plants is an encouraging new landmark 
in plant-based production of HPV VLP vaccines. 
 
A first estimate of final concentration of PsVs yielded figures in the billions per microliter. This 
estimate is an inherently rough one: several assumptions are made, and the starting data – DNA 
concentration obtained by spectrophotometry, is far from accurate. These assumptions are 1) that 
all DNA present was encapsidated pseudogenome DNA, and 2) that each PsV packaged exactly one 
copy of the pseudogenome. However, it is safe to assume these estimates would not be out by more 
than two orders of magnitude. Several other researchers have tried to quantitate PsV concentration 
from various systems, usually using L1 quantitation by ELISA (Fleury et al., 2008a), L1 ELISA in 
combination with PCR (Unckell et al., 1997) or estimating transducing units from reporter assay data 
(Buck et al., 2004). Future improvements on this system will require an accurate estimate of PsV 
concentration, such as that provided by ELISA quantitation.  
 
Total yield and concentration factor were not determined. It is clear from electron micrographs and 
western blots that there was a marked concentration of particles. Western blotting of various stages 
of purification (Figure 3.9) clearly shows an increase in L1 signal, suggesting an approximate doubling 
in concentration from the crude plant sample to the dialysed PsVs. However, this is by no means a 
quantitative assay, and as such no firm conclusions can be reached on that basis. Further work to 
determine PsV concentration is an important next step in evaluating the efficiency of plant 
production of PsVs. 
 
This study successfully demonstrated the feasibility of producing PsVs in plants. However, much 
work remains to fully elucidate the production method and efficiency of production for plant-
produced PsVs to be a feasible alternative to current methods. Most importantly, quantitation of 















as demonstrated by Touze and Coursaget (1998). Another important step is the investigation of all 
DNA species incorporated into virions, to avoid issues of contamination when using these PsVs. 
Lastly, an exciting possibility is a simplified purification protocol. The complexity of the current 
protocol was necessitated by the instability of VLPs. However, the demonstrated stability of these 
PsVs suggest that a much ‘harsher’ virus extraction protocol, such as those used for plant virus 
extraction (E.P. Rybicki, personal communication), could be equally successful in purifying PsVs at a 
fraction of the time and cost.  
3.4.4. PsV testing and PBNA in mammalian cells 
 
For plant-produced PsVs to be a useful tool for vaccine testing, it is vital to demonstrate their use in 
the pseudovirion-based neutralisation assay. PsVs were tested for pseudogenome reporter gene 
expression and PBNA activity using the Great EscAPe SEAP Chemoluminescence Kit (Clontech 
Laboratories, Inc.) or the Luciferase Assay Sytem (Sigma). The Great EscAPe kit is used for the widely 
accepted PBNA protocol developed by the Schiller laboratories, for its sensitivity and ease of use 
(Buck et al., 2005a). Luciferase has seen broad utility as an easy and sensitive reporter assay, and 
was chosen due to its low cost Great EscAPe system, as well as to test an alternative pseudogenome 
size and reporter system. 
 
Of the three PsV types produced, two (mSEAP PsVs and mluc+ PsVs) showed low-level reporter 
activity after pseudoinfection of mammalian cells, while one (mSEAP+) showed little or no reporter 
activity. A preliminary neutralisation assay using a well-established mouse monoclonal HPV-16 
neutralising antibody HPV16.V5 (Christensen et al., 1996a), demonstrated partial neutralisation of 
mSEAP PsV infection, and complete neutralisation of mluc+ PsV infection. It is unclear why mSEAP+ 
PsVs failed to induce reporter gene expression in mammalian cells. The SEAP cassette is clearly 
functional, as demonstrated by successful reporter gene expression by mSEAP PsVs. The plant 
cassette incorporated into the pseudogenome is unlikely to be the cause – mluc+ PsVs also 
incorporated an identical plant expression cassette without affecting expression. It is possible that it 
was due to low concentration of particles in comparison to the other two PsV types – while 
estimates of concentration based on presence of DNA revealed no major differences, electron 
micrographs showed fewer particles in the mSEAP+ PsV samples compared to the other two PsV 
types.  While preliminary, these data provide an initial proof-of-concept for the production of PsVs in 
















Reporter gene expression after pseudoinfection was considerably lower than expected. Most 
previous PBNA studies have needed to dilute PsVs up to 1000000-fold in order to be within the 
linear range of the SEAP assay. Preliminary calculations determined PsV particle concentration to be 
similar to that obtained by Buck et al. (2005a). Accordingly, it would be expected that infectivity 
would be similar. However, this was not the case: the PsVs tested here showed limited reporter gene 
expression, even though they were added undiluted to cells. Expression by pseudoinfection was 
lower than DNA transfected by lipofection. Total DNA added by FuGene transfection to each well of 
a 96-well plate was approximately 200ng per well, while total DNA in a 60µl PsV sample, as 
determined by NanoDrop spectrophotometry, was 500-900ng, depending on the sample. Previous 
work has shown that infectivity of PsVs can be quite low - Roden et al. (1996) estimated an 
infectivity of 1 in 10000 cells, while Unckell et al. (1997) and Touze and Coursaget (1998) estimated 
ratios of 1:2000, 1:1000, respectively. However, this does not fully explain the poor expression 
following pseudoinfection. One consideration is that the PBNA demonstrated by Pastrana et al. 
(2004) used a plasmid (pYSEAP) which included an SV-40 ori. The high level of SEAP expression in 
HEK293TT has been attributed to this feature, and the lack of an SV-40 ori in the SEAP plasmid may 
have resulted in lower-than-expected expression levels. However, it is likely that the major cause of 
this discrepancy is the buffer that the PsVs were dialysed into after purification, namely 0.5M NaCl-
PBS. Changes in cell culture media osmolality (a measure of the concentration of particles in 
solution) have a marked effect on mammalian cells. Physiological osmolality is estimated at 290-
320mOsm/kg for mammalian tissues (Waymouth, 1970). Any major deviation from this, such as the 
introduction of large quantities of NaCl into cell culture media, is likely to seriously affect the growth 
of the cells, as well as their ability to produce recombinant protein. This is likely to be the case here, 
and a priority for future work is to repeat these experiments with PsVs in a buffer with less salt. This 
buffer was chosen because it has been shown to aid in stability of VLPs produced in plants (Varsani 
et al., 2003). However, these PsVs have demonstrated marked stability to denaturing conditions, and 
it is likely that they will be stable in PBS. 
3.5. Conclusion 
 
In conclusion, this study has demonstrated, for the first time, the successful production and testing 
of HPV PsVs in plants. HPV L1/L2 VLPs, as well as PsVs containing a mammalian reporter cassette 
pseudogenome, were produced in large quantities in planta. The particles readily encapsidated the 
pseudogenome DNA provided by the replicating vectors. Further, they were easily purified, stable at 
high temperature, and were conformationally indeterminable from PsVs produced in other systems. 















preliminary proof-of-concept study only, it demonstrates that transient plant-based production of 
HPV PsVs is a feasible strategy, and should be further investigated as low cost alternative to 
















Chapter 4: Conclusions 
 
Production of neutralising antibodies to HPV is currently regarded as the means of protection 
elicited by HPV vaccines. The best estimate of protective efficacy relies on using the widely accepted 
pseudovirion neutralisation assay (PBNA) for evaluation of the neutralising potential of anti-HPV 
sera. While the currently accepted  PBNA, as described by Buck et al. (2005a), is a sensitive and 
efficient assay, production of PsV stocks used in this assay relies on expensive mammalian cell 
culture. As such, there is a perceived need to reduce the costs of current PsV production technology. 
Transient expression in plants offers an attractive alternative to mammalian cell culture for this 
purpose, with the potential for a more cost effective PsV production method. The aims of this 
project were to 1) develop replicating plant vectors for the production of PsV pseudogenomes in 
plants, 2) co-infiltrate plants with these vectors, along with HPV-16 L1 and L2 expression vectors, to 
produce PsVs in planta by transient expression, and purify those particles, and 3) test the efficacy of 
these plant-produced PsVs for use in a pseudovirion-based neutralisation assay. 
4.1. Design and construction of replicating vectors for pseudogenome 
production in N. benthamiana and testing in mammalian cells 
 
Three novel replicating vectors were successfully created from the replicating plant expression 
vector pRIC3; namely pRIC3-mSEAP, pRIC3-mSEAP+, and pRIC3-mluc+. The autonomously replicating 
vector pRIC, and its successor pRIC3, were previously developed from Bean yellow dwarf mastrevirus 
(BeYDV) for transient expression of recombinant protein at high levels in plants. pRIC and pRIC3 have 
both been demonstrated to form an autonomously replicating replicon in plant cells which replicates 
to high copy number as a dsDNA episome (Regnard et al., 2010). This replication to high copy 
number makes pRIC3 an ideal vector for the production of large quantities of reporter 
pseudogenomes in plant cells. pRIC3-mSEAP was created by insertion of mammalian EF-1α promoter 
element, SEAP gene, and mammalian SV40 polyadenylation signal, in place of the extant plant 
cassette. pRIC3-mSEAP+ was created by insertion of the same mammalian cassette, at the 5’-end of 
the plant cassette. pRIC3-mluc+ was created by insertion of a mammalian CMV 
intron/enhancer/promoter element, pCapR enhancer element, luciferase reporter gene, and BGH 
polyadenylation signal, at the 5’ end of the extant plant cassette. These three vectors were designed 
to test a range of replicon sizes (4.8, 6.6 and 7.6Kbp, respectively) when agroifiltrated into plants, for 
















All three vectors were confirmed to have the correct sequences, and were tested for reporter gene 
functionality in mammalian cells. Transfection of mammalian cells with plasmid DNA resulted in 
reporter gene expression for all three vectors, as determined by western blotting for SEAP, and 
commercial luciferase assay for luc. This confirmed that these vectors were fully functional under 
the control of a mammalian promoter, and that they would provide a suitable mechanism of 
pseudogenome production for PsVs produced in planta.  Further, it validated the choice of SEAP and 
luc as robust and reliable reporter genes for this application. 
4.2. Production and purification of HPV-16 VLPs and PsVs in N. 
benthamiana via agroinfiltration of transient expression vectors 
 
In order to use the replicating vectors for transient production of pseudogenome DNA, these vectors 
needed to demonstrate replicon formation and replication to high copy number in planta. Vector-
specific replicon formation was demonstrated for each replicating vector by inverse PCR. qPCR was 
used to evaluate the gene copy number increase after agroinfiltration of plants. All three replicating 
vectors showed a 100-1000-fold increase in gene copy number from 1 to 3dpi. This increase closely 
mimics the copy number increase seen in pRIC and pRIC3 (Regnard et al., 2010) 
 
For transient expression of the HPV-16 major and minor capsid proteins in plants, non-replicating 
plant expression constructs pTRAc-hL1 and pTRAc-hL2 were chosen. pTRAc is a transient expression 
vector, which targets protein expression to the cytoplasm of plants. pTRAc constructs encoding 
human codon-optimised HPV16 L1 and HPV16 L2 proteins (hL1 and hL2) have demonstrated high 
levels of protein expression in plants, compared to wildtype and plant codon-optimised genes, as 
well as to other vectors (Maclean et al., 2007; Pereira, 2008). The highest expression of all elements 
(L1, L2 and DNA replicons) was seen at 3-5dpi. Accordingly, 4dpi was chosen as the time at which to  
harvest plants co-infiltrated with pTRAc-hL1 and pTRAc-hL2 alone, as well as with each of pRIC3-
mSEAP, pRIC3-mSEAP+, and pRIC3-mluc+ individually. Purification of particles was successful, using a 
density gradient ultracentrifugation method for purification developed by Varsani et al. (2003) for 
the purification of HPV-16 VLPs from plants. Dot blot testing for presence of L1 in density gradient 
fractions identified putative PsVs in fractions corresponding to the expected buoyant density of 
PsVs, for all three PsV types (i.e. mSEAP, mSEAP+ and mluc+ PsVs), with little or no L1 signal at the 
expected buoyant density for empty VLPs. These fractions were pooled and electron microscopy 
confirmed the presence of abundant PsV particles, of a size range from 30-120nm. PsVs of the 
expected size (40-70nm) constituted approximately 54% (mSEAP PsVs), 47% (mSEAP+ PsVs) and 50% 















L1 and L2 were present in all PsVs, as well as VLPs, produced. L1 presence was fairly consistent, 
while levels of L2 expression (as seen by western blot) varied between different PsV types and 
biological repeats. This is unsurprising, considering that the ratio of L1:L2 is variously reported at 5:1, 
12:1 and 30:1, and there is some evidence for variation of this ratio based on amount of L2 present 
during VLP assembly (Buck et al., 2008). Inverse PCR testing of DNA from PsVs revealed that each 
PsV type successfully encapsidated pseudogenome DNA, and that this DNA was protected by the PsV 
capsid shell. Proteinase K digestion of PsVs abrogated this protection, to confirm that DNA was 
encapsidated by PsVs, rather than merely associated with them. 
4.3. Pseudoinfection of mammalian cells with purified plant-produced 
PsVs, and their use for the PBNA 
 
In order for plant-produced HPV-16 PsVs to be useful for vaccine testing, there is a need to 
demonstrate their effectiveness for pseudoinfection of mammalian cells, as well as neutralisation of 
PsVs with HPV-16 neutralising antibodies. To achieve this, plant produced HPV PsVs were used to 
pseudoinfect mammalian cells. Reporter gene activity was assayed 72 hours post-infection, using 
luciferase or SEAP assays. pRIC3-mSEAP and pRIC3-mluc+ demonstrated successful reporter activity 
following pseudoinfection of mammalian cells, while pRIC3-mSEAP+ showed no activity at 72 hours 
post-infection. Further, incubation of PsVs with a well-known neutralising HPV16 antibody HPV16.V5 
resulted in partial neutralisation of mSEAP PsVs, and complete neutralisation of mluc+ PsVs, as 
shown by abrogation of reporter gene signal. Overall, reporter gene expression following 
pseudoinfection of mammalian cells was lower than expected, given the high concentration of PsVs 
produced. However, this is likely as a result of the high-salt PBS buffer that purified PsVs were stored 
in. Further work is needed to test whether this hypothesis is accurate. As a result, this work has not 
yet produced usable PsVs, but has demonstrated a feasible production and purification strategy. 
4.4. Conclusions and further work 
 
Replicating vectors were successfully designed and constructed for the production of HPV-16 PsV 
pseudogenomes, incorporating luc and SEAP mammalian expression cassettes. Pseudogenomes of 
4.8, 6.4 and 7.4Kbp were all produced and packaged with similar efficacy, and L1/L2 VLPs assembled 
readily in the absence of replicon DNA. Two out of the three PsVs produced (MSEAP and mluc+) 
were successfully used for a PBNA, while mSEAP+ PsVs did not result in reporter gene expression in 
mammalian cells. This preliminary proof-of-concept study was successful using two of the three PsV 















accurate estimate of PsV concentration would be of great value to determine whether plant-based 
production is favourable to the current mammalian cell culture production protocol. An evaluation 
of all DNA species present in the PsVs produced would be of great value if these particles are ever to 
be used for vaccine formulations. The PBNA work performed was preliminary, and requires 
optimisation. Repeating this work using PsVs in a low-salt buffer is a vital step to properly evaluate 
the potential of these particles for PBNA applications. In conclusion, transient plant-based 
expression of HPV capsid proteins, used in conjunction with replicating vectors for pseudogenome 
















Appendix A: Recipes 
 
Complete DMEM (cDMEM) 
500ml Dulbecco’s Modified Eagles Medium (DMEM) 
50ml Foetal Calf Serum (FCS) 
5ml penicillin/streptomycin (10mg/ml) 
5ml Non-essential amino acids (NEAA) 
 
Neutralisation media 
500ml Dulbecco’s Modified Eagles Medium (DMEM) without phenol red 
50ml Foetal Calf Serum (FCS) 
5ml penicillin/streptomycin (10mg/ml) 
5ml Non-essential amino acids (NEAA) 
 
Blocking Buffer 
100ml 10X PBS 
1ml 10% Tween-20 
5g Skim-milk powder  
ddH2O to 100ml 
 
Transfer Buffer (1X) 
28.8g Glycine 
6.04g Tris Base 
200ml Methanol 
ddH2O to 1L 
 
Running Buffer (1X) 
28.8g Glycine 
6.04g Tris base 
2g Sodium dodecyl sulphate (SDS) 
ddH2O to 2L 
 
Coommassie Stain 
1g Coomassie R250 
100ml glacial acetic acid 
400ml methanol 
























5g Yeast Extract 




10g Tryptone  
10g NaCl 
5g Yeast Extract 
ddH2O to 1L 















ddH2O to 1L 
pH to 5.6 
Autoclave 
 
5X Protein loading dye 
940µl 10% SDS 
470µl 1M TrisCl 




1mg bromophenol blue 
 
10X Tris-Borate-EDTA (TBE) Electrophoresis Buffer 
108g Tris base 
55g Boric acid 
7.5g EDTA 






















Adjust to pH 7.4 




100ml 1X PBS 
29.22g NaCl 
ddH2O to 1L 
 
CsCl-PBS 
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